



**Cochrane**  
**Library**

Cochrane Database of Systematic Reviews

## Band ligation versus no intervention for primary prevention of upper gastrointestinal bleeding in adults with cirrhosis and oesophageal varices (Review)

Vadera S, Yong CWK, Gluud LL, Morgan MY

Vadera S, Yong CWK, Gluud LL, Morgan MY.

Band ligation versus no intervention for primary prevention of upper gastrointestinal bleeding in adults with cirrhosis and oesophageal varices.

*Cochrane Database of Systematic Reviews* 2019, Issue 6. Art. No.: CD012673.

DOI: 10.1002/14651858.CD012673.pub2.

[www.cochranelibrary.com](http://www.cochranelibrary.com)

## TABLE OF CONTENTS

HEADER . . . . .	1
ABSTRACT . . . . .	1
PLAIN LANGUAGE SUMMARY . . . . .	2
SUMMARY OF FINDINGS FOR THE MAIN COMPARISON . . . . .	4
BACKGROUND . . . . .	7
OBJECTIVES . . . . .	8
METHODS . . . . .	8
RESULTS . . . . .	12
Figure 1. . . . .	13
Figure 2. . . . .	15
Figure 3. . . . .	16
Figure 4. . . . .	18
Figure 5. . . . .	19
Figure 6. . . . .	20
DISCUSSION . . . . .	21
AUTHORS' CONCLUSIONS . . . . .	24
ACKNOWLEDGEMENTS . . . . .	25
REFERENCES . . . . .	25
CHARACTERISTICS OF STUDIES . . . . .	29
DATA AND ANALYSES . . . . .	41
Analysis 1.1. Comparison 1 Band ligation versus no intervention, Outcome 1 Mortality, by liver injury. . . . .	43
Analysis 1.2. Comparison 1 Band ligation versus no intervention, Outcome 2 Mortality, by size of varices. . . . .	44
Analysis 1.3. Comparison 1 Band ligation versus no intervention, Outcome 3 Upper gastrointestinal bleeding, by liver injury. . . . .	45
Analysis 1.4. Comparison 1 Band ligation versus no intervention, Outcome 4 Upper gastrointestinal bleeding, by size of varices. . . . .	46
Analysis 1.5. Comparison 1 Band ligation versus no intervention, Outcome 5 Serious adverse events, by liver injury. . . . .	47
Analysis 1.6. Comparison 1 Band ligation versus no intervention, Outcome 6 Serious adverse events, by size of varices. . . . .	48
Analysis 1.7. Comparison 1 Band ligation versus no intervention, Outcome 7 Variceal bleeding, by liver injury. . . . .	49
Analysis 1.8. Comparison 1 Band ligation versus no intervention, Outcome 8 Variceal bleeding, by size of varices. . . . .	50
Analysis 2.1. Comparison 2 Band ligation versus no intervention: worst-case, extreme worst-case, and extreme best-case scenario analyses, Outcome 1 Mortality. . . . .	51
Analysis 2.2. Comparison 2 Band ligation versus no intervention: worst-case, extreme worst-case, and extreme best-case scenario analyses, Outcome 2 Upper gastrointestinal bleeding. . . . .	52
Analysis 2.3. Comparison 2 Band ligation versus no intervention: worst-case, extreme worst-case, and extreme best-case scenario analyses, Outcome 3 Serious adverse events. . . . .	54
Analysis 2.4. Comparison 2 Band ligation versus no intervention: worst-case, extreme worst-case, and extreme best-case scenario analyses, Outcome 4 Variceal bleeding. . . . .	55
ADDITIONAL TABLES . . . . .	56
APPENDICES . . . . .	62
CONTRIBUTIONS OF AUTHORS . . . . .	64
DECLARATIONS OF INTEREST . . . . .	64
SOURCES OF SUPPORT . . . . .	65
DIFFERENCES BETWEEN PROTOCOL AND REVIEW . . . . .	65

[Intervention Review]

# Band ligation versus no intervention for primary prevention of upper gastrointestinal bleeding in adults with cirrhosis and oesophageal varices

Sonam Vadera<sup>1</sup>, Charles Wei Kit Yong<sup>1</sup>, Lise Lotte Gluud<sup>2</sup>, Marsha Y Morgan<sup>1</sup>

<sup>1</sup>UCL Institute for Liver & Digestive Health, Division of Medicine, Royal Free Campus, University College London, London, UK.

<sup>2</sup>Gastrounit, Medical Division, Copenhagen University Hospital Hvidovre, Hvidovre, Denmark

Contact address: Marsha Y Morgan, UCL Institute for Liver & Digestive Health, Division of Medicine, Royal Free Campus, University College London, Rowland Hill Street, Hampstead, London, NW3 2PF, UK. [marsha.morgan@ucl.ac.uk](mailto:marsha.morgan@ucl.ac.uk).

**Editorial group:** Cochrane Hepato-Biliary Group.

**Publication status and date:** New, published in Issue 6, 2019.

**Citation:** Vadera S, Yong CWK, Gluud LL, Morgan MY. Band ligation versus no intervention for primary prevention of upper gastrointestinal bleeding in adults with cirrhosis and oesophageal varices. *Cochrane Database of Systematic Reviews* 2019, Issue 6. Art. No.: CD012673. DOI: 10.1002/14651858.CD012673.pub2.

Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

## ABSTRACT

### Background

The presence of oesophageal varices is associated with the risk of upper gastrointestinal bleeding. Endoscopic variceal ligation is used to prevent this occurrence but the ligation procedure may be associated with complications.

### Objectives

To assess the beneficial and harmful effects of band ligation versus no intervention for primary prevention of upper gastrointestinal bleeding in adults with cirrhosis and oesophageal varices.

### Search methods

We combined searches in the Cochrane Hepato-Biliary Group Controlled Trials Register, the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase, LILACS, and Science Citation Index with manual searches. The last search update was 9 February 2019.

### Selection criteria

We included randomised clinical trials comparing band ligation versus no intervention regardless of publication status, blinding, or language in the analyses of benefits and harms, and observational studies in the assessment of harms. Included participants had cirrhosis and oesophageal varices with no previous history of variceal bleeding.

### Data collection and analysis

Three review authors extracted data independently. The primary outcome measures were all-cause mortality, upper gastrointestinal bleeding, and serious adverse events. We undertook meta-analyses and presented results using risk ratios (RRs) with 95% confidence intervals (CIs) and  $I^2$  values as a marker of heterogeneity. In addition, we calculated the number needed to treat to benefit (NNTTB) for the primary outcomes. We assessed bias control using the Cochrane Hepato-Biliary domains; determined the certainty of the evidence using GRADE; and conducted sensitivity analyses including Trial Sequential Analysis.

---

**Band ligation versus no intervention for primary prevention of upper gastrointestinal bleeding in adults with cirrhosis and oesophageal varices (Review)**

Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

## Main results

Six randomised clinical trials involving 637 participants fulfilled our inclusion criteria. One of the trials included an additional small number of participants (< 10% of the total) with non-cirrhotic portal hypertension/portal vein block. We classified one trial as at low risk of bias for the outcome, mortality and high risk of bias for the remaining outcomes; the five remaining trials were at high risk of bias for all outcomes. We downgraded the evidence to moderate certainty due to the bias risk. We gathered data on all primary outcomes from all trials. Seventy-one of 320 participants allocated to band ligation compared to 129 of 317 participants allocated to no intervention died (RR 0.55, 95% CI 0.43 to 0.70;  $I^2 = 0\%$ ; NNTTB = 6 persons). In addition, band ligation was associated with reduced risks of upper gastrointestinal bleeding (RR 0.44, 95% CI 0.28 to 0.72; 6 trials, 637 participants;  $I^2 = 61\%$ ; NNTTB = 5 persons), serious adverse events (RR 0.55, 95% CI 0.43 to 0.70; 6 trials, 637 participants;  $I^2 = 44\%$ ; NNTTB = 4 persons), and variceal bleeding (RR 0.43, 95% CI 0.27 to 0.69; 6 trials, 637 participants;  $I^2 = 56\%$ ; NNTTB = 5 persons). The non-serious adverse events reported in association with band ligation included oesophageal ulceration, dysphagia, odynophagia, retrosternal and throat pain, heartburn, and fever, and in the one trial involving participants with either small or large varices, the incidence of non-serious side effects in the banding group was much higher in those with small varices, namely ulcers: small versus large varices 30.5% versus 8.7%; heartburn 39.2% versus 17.4%. No trials reported on health-related quality of life.

Two trials did not receive support from pharmaceutical companies; the remaining four trials did not provide information on this issue.

## Authors' conclusions

This review found moderate-certainty evidence that, in patients with cirrhosis, band ligation of oesophageal varices reduces mortality, upper gastrointestinal bleeding, variceal bleeding, and serious adverse events compared to no intervention. It is unlikely that further trials of band ligation versus no intervention would be considered ethical.

## PLAIN LANGUAGE SUMMARY

### Band ligation versus no intervention for primary prevention of upper gastrointestinal bleeding in people with cirrhosis and oesophageal varices

#### Background

Cirrhosis is a chronic disorder of the liver. People with cirrhosis may develop dilated veins in their oesophagus, and these may bleed. Variceal bleeding is potentially life-threatening. Band ligation is a procedure in which a viewing instrument or endoscope is inserted through the mouth into the oesophagus and the varices are then tied off at their base, thereby cutting off the blood flow. The varices have to be sufficiently large to allow the bands to be applied. This procedure can be done before people bleed from their varices (primary prevention) or after they have suffered a bleed (secondary prevention).

#### Review question

We investigated the benefits and harms of band ligation compared with no treatment, for primary prevention of bleeding in people with cirrhosis and oesophageal varices by reviewing clinical trials in which people were randomly allocated (chosen by chance) to band ligation or no treatment.

#### Search date

9 February 2019.

#### Trial funding sources

Two of the included trials did not receive funding or support from for-profit companies; the remaining four trials did not provide information on this issue.

#### Trial characteristics

We included six randomised clinical trials involving 637 participants. All randomised clinical trials compared band ligation to no treatment. One trial included participants with and without cirrhosis. The length of time taken to eradicate the varices, where reported, ranged from a mean of 28 to 76 days.

#### Key results

---

**Band ligation versus no intervention for primary prevention of upper gastrointestinal bleeding in adults with cirrhosis and oesophageal varices (Review)** 2

Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Our analyses showed a beneficial effect of band ligation on the rates of death, bleeding, and serious adverse events compared to no treatment.

#### **Certainty of the evidence**

In people with cirrhosis and oesophageal varices, the risk of death associated with variceal bleeding is very high as are the risks of other serious harms. Our review has found that band ligation reduces the risks of these problems when compared to no treatment. We are moderately confident in our estimates of the benefits and harms of band ligation. It is unlikely that any further trials comparing band ligation versus no intervention will be undertaken.

## SUMMARY OF FINDINGS FOR THE MAIN COMPARISON *[Explanation]*

Band ligation compared to no intervention for primary prevention of upper gastrointestinal bleeding in adults with oesophageal varices						
<b>Patient or population:</b> adults with oesophageal varices <b>Setting:</b> hospital <b>Intervention:</b> band ligation <b>Comparison:</b> no intervention						
Outcomes*	Anticipated absolute effects** (95% CI)		Relative effect (95%CI)	Number of participants (Studies (n))	Certainty of the evidence (GRADE)	Comments
	Risk with no intervention	Risk with band ligation				
Mortality	Study population		RR 0.55 (0.43 to 0.70)	637 (6 RCTs)	⊕⊕⊕○ Moderate <sup>a</sup>	Only one trial was at low risk of bias in the overall assessment
	407 per 1000	224 per 1000 (175 to 285)				
Upper gastrointestinal bleeding	Study population		RR 0.44 (0.28 to 0.72)	637 (6 RCTs)	⊕⊕⊕○ Moderate <sup>a</sup>	All trials were at high risk of bias in the overall assessment
	410 per 1000	180 per 1000 (115 to 295)				
Serious adverse events	Study population		RR 0.55 (0.43 to 0.70)	637 (6 RCTs)	⊕⊕⊕○ Moderate <sup>a</sup>	All trials were at high risk of bias in the overall assessment
	634 per 1000	349 per 1000 (273 to 444)				
Variceal bleeding	Study population		RR 0.43 (0.27 to 0.69)	637 (6 RCTs)	⊕⊕⊕○ Moderate <sup>a</sup>	All trials were at high risk of bias in the overall assessment
	385 per 1000	166 per 1000 (104 to 266)				



**GRADE Working Group grades of evidence**

**High certainty:** we are very confident that the true effect lies close to that of the estimate of the effect.

**Moderate certainty:** we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.

**Low certainty:** our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.

**Very low certainty:** we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect

<sup>a</sup>We downgraded the certainty of the evidence by one level due to the lack of trials with a low risk of bias.

## BACKGROUND

### Description of the condition

Portal hypertension is a very common and serious complication of cirrhosis. It develops as a result of increased vascular resistance to portal flow (D'Amico 1999). In people with cirrhosis this resistance develops as a result of an increase in liver stiffness secondary to the development of scar tissue and regenerating nodules within the hepatic parenchyma (Moreau 2006). In addition, changes occurring in the liver sinusoids also play a role. These mechanical factors account for approximately 70% of the increase in hepatic resistance to portal blood flow. The remaining 30% is due to active contraction of sinusoidal stellate cells, myofibroblasts in the portal tract and vascular smooth muscle cells in the hepatic vasculature and sinusoidal endothelial cell dysfunction, which increase vasoconstrictor drive (Bosch 2015; Brunner 2017; Iwakiri 2014). The increased pressure within the portal system causes blood to be redirected through vessels with less vascular resistance, in particular anastomoses or shunts between the portal and systemic vasculature. These 'portal-systemic collaterals' can develop in several sites within the body; the most important being the lower end of the oesophagus where they appear, on endoscopy, as dilated tortuous submucosal veins or 'varices' protruding into the lumen. Portal hypertension is defined as a hepatic venous pressure gradient of more than 5 mm Hg. However, the risk of developing oesophageal varices does not increase until the pressure reaches 10 mm Hg (Ripoli 2007). Thus, a hepatic venous pressure gradient of 10 mm Hg or higher is termed 'clinically significant portal hypertension'. The most common cause of portal hypertension is cirrhosis but it can also develop in the absence of cirrhosis, a condition referred to as 'non-cirrhotic portal hypertension.' The best known causes of non-cirrhotic portal hypertension are vascular changes such as portal vein block or severe hepatic fibrosis short of cirrhosis, as seen in schistosomiasis.

The development of oesophageal varices is one of the most significant consequences of portal hypertension, as these vessels are prone to rupture, resulting in sometimes catastrophic gastrointestinal bleeding with a high associated morbidity and mortality. Approximately 30% of people with cirrhosis have oesophageal varices when diagnosed with liver disease (D'Amico 1995; D'Amico 1999; D'Amico 2007; De Lisi 2010). Varices develop at a rate of 5% to 9% per year in people without varices at presentation (Groszman 2005; Merli 2003); the rate of progression from small to large varices is about 10% per year (Merli 2003). Varices are more common in people with severe liver disease; thus, they are found in approximately one-third of people with well-compensated cirrhosis but in around 90% of people with severely decompensated disease (Kovalak 2007).

The incidence of variceal haemorrhage in people with cirrhosis and oesophageal varices is approximately 10% to 15% per year (Groszman 2005; NIEC 1988). A number of risk factors for

bleeding have been identified, including: (i) the severity of liver disease; (ii) the size of the varices and their endoscopic appearance - large and pellucid varices with red whale markings (areas of thinning of the variceal wall), are more likely to bleed than small varices (D'Amico 1999; NIEC 1988); and, (iii) the degree of portal hypertension - bleeding is more likely to occur when the hepatic venous pressure gradient is more than 12 mmHg (Groszmann 1990). Without some form of intervention, bleeding usually recurs within one to two years after an incident event (Bosch 2003).

Although the in-hospital mortality associated with variceal bleeding has decreased in recent years due to improvements in endoscopic therapy and the use of antibiotic prophylaxis, the reported mortality rate still lies between 12% to 44%. The risk of death within six weeks of the initial variceal haemorrhage is below 10% in Child-Pugh Class A and greater than 32% in those in Child-Pugh Class C (Carbonell 2004).

### Description of the intervention

As the incidence of variceal bleeding in people with cirrhosis and oesophageal varices is approximately 10% to 15% per year and the mortality rate associated with a first bleed is 12% to 44% then it is clear that prophylactic regimens to prevent bleeding are important (Garcia-Tsao 2007; Garcia-Tsao 2008). Drugs that reduce the portal flow or the hepatic vascular resistance, or both, such as non-selective beta-blockers will reduce the azygos blood flow and variceal pressure and have been shown to effectively prevent variceal bleeding and to reduce bleeding-associated mortality (Lebrec 1981; Poynard 1991). However, approximately 15% of people with cirrhosis may have absolute or relative contraindications to the use of non-selective beta-blockers, for example, peripheral vascular diseases, diabetes mellitus, chronic obstructive pulmonary disease and asthma. Adverse effects, such as fatigue, weakness, and shortness of breath are common, and may result in the need to reduce the dose or even to discontinue the drug in a further 15% of people with cirrhosis (Longacre 2008). In addition, a long-term satisfactory haemodynamic response is only obtained in 33% to 50% of treated patients (Albillos 2007; Bosch 2003; García-Pagán 1990; Reiberger 2013). Endoscopic obliteration of the varices provides an alternative management option (Gluud 2007; Tripathi 2007; van Buuren 2003). Variceal sclerotherapy, which involves injecting a strong and irritating sclerosant or glue, is associated with serious adverse events including severe bleeding and oesophageal strictures (Schmitz 2001). Band ligation may provide a safer option (Gluud 2007).

### How the intervention might work

Banding devices use a means of capturing the target tissue, in this case an oesophageal varix, while a small diameter circular band is

deployed around its base (ASGE 2008). The band may be rubber, latex, or a similar material. The ligation procedure results in tight compression with vascular compromise leading to thrombosis, necrosis, and sloughing. As sufficient tissue needs to be captured in order to allow placement of the bands, this technique can not be used successfully in people with small varices and so is only used in people with medium to large varices. Previous banding devices used an overtube for the repeated intubation, allowing the placement of multiple bands (Collins 2001). The insertion of an overtube is associated with adverse events including perforation of the oesophagus (Gluud 2007; Gluud 2012; Wong 2000). At present, multiband devices (without an overtube) are used, resulting in considerably fewer adverse events (ASGE 2008). Several sessions of banding are normally required to completely eradicate the varices and are undertaken over a period of weeks; in addition, ongoing long-term endoscopic surveillance is required to check for variceal recurrence.

### Why it is important to do this review

The annual risk of people with cirrhosis developing varices, in European countries, is 7% to 8%, and the annual risk of bleeding from these varices is 5% to 15% (Asrani 2013). A number of pharmacological and endoscopic interventions have improved prognosis in patients with variceal haemorrhage, but six-week mortality rates remain high at 15% to 20% (Carbonell 2004; Chalasani 2003; D'Amico 2003; Hobolth 2010). The management of people with variceal bleeding is expensive, hence it is important to identify interventions that are both clinically effective and cost-effective (Thabut 2007).

Several randomised clinical trials have found that band ligation has beneficial effects on a number of important outcomes, including mortality and gastrointestinal bleeding, when used for primary prevention in people with cirrhosis when compared to no intervention (Chen 1997; Lay 1997; Lo 1999; Sarin 1996; Svoboda 1999; Triantos 2005). Although these results have been confirmed in a number of meta-analyses (Bedi 2000; Imperiale 2001; Triantos 2005; Vlachogiannakos 2000), these have invariably included trials involving a high proportion of participants with non-cirrhotic portal hypertension. Thus, the benefit of band ligation for the primary prevention of gastrointestinal bleeding in patients with cirrhosis and oesophageal varices remains unclear. This systematic review with meta-analyses aims to clarify this situation.

## OBJECTIVES

To assess the beneficial and harmful effects of band ligation versus no intervention for primary prevention of upper gastrointestinal bleeding in adults with cirrhosis and oesophageal varices.

## METHODS

### Criteria for considering studies for this review

#### Types of studies

We included randomised clinical trials regardless of their publication status, blinding or language in our primary analyses. If, during the selection of trials, we identified observational studies (i.e. quasi-randomised studies; cohort studies; or case series) which reported adverse events caused by, or associated with, the interventions under review, and which included comparative control data, we included them for that purpose. We did not specifically search for observational studies for inclusion in this review, which is a known limitation.

#### Types of participants

We included adult participants (> 18 years) with cirrhosis and endoscopically verified oesophageal varices that had not bled, irrespective of the size of the varices or the hepatic venous pressure gradient. We did not include participants with non-cirrhotic portal hypertension unless they comprised < 10% of the total population or separate analyses were provided for this participants subgroup.

#### Types of interventions

We compared band ligation versus no intervention. It would be very difficult to adequately double-blind the banding procedure, and as the use of sham procedures would not be of any benefit to participants and might have an associated morbidity, their use might be considered unethical. We did not compare band ligation versus non-selective beta-blockers due to overlap with another review (Gluud 2012). We allowed effective cointerventions if administered equally to the intervention and control groups.

#### Types of outcome measures

We assessed all outcomes at the maximum duration of follow-up.

#### Primary outcomes

- All-cause mortality
- Upper gastrointestinal bleeding, using the definitions applied by primary investigators
  - Serious adverse events. We defined adverse events as any untoward medical occurrence and considered adverse events as serious if they resulted in death, were life-threatening, required inpatient hospitalisation or prolongation of existing hospitalisation, or resulted in persistent or significant disability or incapacity (ICH-GCP 1997). In this review, serious adverse events included mortality and upper gastrointestinal bleeding,

and we analysed them as a composite outcome ([hbg.cochrane.org/information-authors](http://hbg.cochrane.org/information-authors)).

### Secondary outcomes

- Variceal bleeding
- Non-serious adverse events, defined as all adverse events that did not fulfil the criteria for serious adverse events ( *ICH GCP 1997*)
- Health-related quality of life

### Search methods for identification of studies

We combined the electronic and manual searches.

#### Electronic searches

We searched the Cochrane Hepato-Biliary Group Controlled Trials Register ( [hbg.cochrane.org/specialised-register](http://hbg.cochrane.org/specialised-register); February 2019), the Cochrane Central Register of Controlled Trials (CENTRAL; 2019, Issue 2) in the Cochrane Library, MEDLINE Ovid (1946 to February 2019), Embase Ovid (1974 to February 2019), LILACS (Bireme; 1982 to February 2019), Science Citation Index Expanded (Web of Science; 1900 to February 2019), and Conference Proceedings Citation Index - Science (Web of Science; 1990 to February 2019) (*Royle 2003*), using the strategies described in [Appendix 1](#).

We did not have access to Chinese, Russian, or Japanese databases. We plan to search these additional databases in future updates, should they become available via the Cochrane Hepato-Biliary Group.

#### Searching other resources

We searched the reference lists of papers identified in the electronic searches and the 2000 to 2018 conference proceedings of the British Society for Gastroenterology (BSG), the British Association for the Study of the Liver (BASL), the European Association for the Study of the Liver (EASL), the United European Gastroenterology Week (UEGW), the American Gastroenterological Association (AGA), and the American Association for the Study of Liver Diseases (AASLD). We wrote to the principal authors of randomised clinical trials and the device companies for additional information about completed randomised clinical trials and for information about any ongoing randomised clinical trials. We also searched online trial registries such as ClinicalTrials.gov ( [clinicaltrials.gov/](http://clinicaltrials.gov/)), European Medicines Agency (EMA) ( [www.ema.europa.eu/ema/](http://www.ema.europa.eu/ema/)), World Health Organization (WHO) International Clinical Trial Registry Platform ( [www.who.int/ictpr](http://www.who.int/ictpr)), and the Food and Drug Administration (FDA) ( [www.fda.gov](http://www.fda.gov)), for ongoing or unpublished trials. In addition, we searched Google Scholar using the terms (band\* OR ligat\*) AND bleed\* AND varic\* AND cirrhosis.

### Data collection and analysis

We performed the review following the recommendations in the *Cochrane Handbook for Systematic Reviews of Interventions* (*Higgins 2011*), the Cochrane Hepato-Biliary Group ( [hbg.cochrane.org/](http://hbg.cochrane.org/)), and the MECIR guidelines (*MECIR 2018*).

### Selection of studies

All review authors participated in the literature searches, identified trials eligible for inclusion, and participated in the decisions regarding the eligibility of trials for consideration. We reached the final selection through discussion; LGG acted as ombudsman where agreement could not be reached through discussion. We listed the excluded trials with the reason for their omission. For randomised clinical trials reported in more than one publication, we selected the paper reporting the longest duration of follow-up as the primary reference.

### Data extraction and management

Three review authors (SV, CWKY and MYM) independently extracted data from the included trials data and evaluated bias. The collected data included information on the following.

1. Trials: design (cross-over or parallel), settings (number of clinical sites; outpatient or inpatient; inclusion period), country of origin; publication status; funding sources.
2. Participants: mean age, proportion of men, aetiology of cirrhosis, proportion with Child-Pugh A/B/C; endoscopic findings; classification of varices (based on the primary authors' definition).
3. Interventions: equipment used; operator experience; technique; endpoint and whether achieved and within what time scale; number of banding sessions, number of bands used per session; cointerventions.
4. Outcomes: including definitions used in the assessment and duration of follow-up; number of participants included in the assessment of outcomes (number of losses to follow-up/withdrawals); outcomes included in the meta-analyses.

We gathered the primary and secondary outcome data, including the criteria used in the definition of high and low risk varices, methods and definitions used to assess bleeding.

If we could not find the relevant data in the published trial reports, we wrote to the primary investigators to ask for the necessary information.

### Assessment of risk of bias in included studies

We followed Cochrane Hepato-Biliary Group recommendations for assessing the risk of bias in the included trials, based on the definitions described below ( [hbg.cochrane.org/information-authors](http://hbg.cochrane.org/information-authors)). We assessed each domain separately as recommended in the *Cochrane Handbook for Systematic Reviews of Interventions* (*Higgins 2017*), and combined the domains into an overall score.

We classified trials as low risk of bias only if none of the domains was designated as being at unclear or high risk of bias.

#### **Allocation sequence generation**

- Low risk of bias: sequence generation was achieved using computer random number generation or a random number table. Drawing lots, tossing a coin, shuffling cards, and throwing dice were adequate if performed by an independent person not otherwise involved in the trial.
- Uncertain risk of bias: the method of sequence generation was not specified.
- High risk of bias: the sequence generation method was not random.

#### **Allocation concealment**

- Low risk of bias: the participant allocations could not have been foreseen in advance of, or during, enrolment. Allocation was controlled by a central and independent randomisation unit. The allocation sequence was unknown to the investigators (e.g. if the allocation sequence was hidden in sequentially numbered, opaque, and sealed envelopes).
- Uncertain risk of bias: the method used to conceal the allocation was not described so that intervention allocations may have been foreseen in advance of, or during, enrolment.
- High risk of bias: the allocation sequence was likely to be known to the investigators who assigned the participants.

#### **Blinding of participants and personnel**

- Low risk of bias: blinding of participants and personnel performed adequately using a placebo. We defined lack of blinding as not likely to affect the evaluation of mortality (Savović 2012a; Savović 2012b).
- Unclear risk of bias: insufficient information to assess blinding.
- High risk of bias: no blinding or incomplete blinding.

#### **Blinding of outcome assessors**

- Low risk of bias: blinding of outcome assessors performed adequately using a placebo. We defined lack of blinding as not likely to affect the evaluation of mortality (Savović 2012a; Savović 2012b).
- Unclear risk of bias: there was insufficient information to blinding.
- High risk of bias: no blinding or incomplete blinding.

#### **Incomplete outcome data**

- Low risk of bias: missing data were unlikely to make treatment effects depart from plausible values. Sufficient

methods, such as multiple imputation, were employed to handle missing data.

- Uncertain risk of bias: there was insufficient information to assess whether missing data in combination with the method used to handle missing data were likely to induce bias on the results.
- High risk of bias: the results were likely to be biased due to missing data.

#### **Selective outcome reporting**

- Low risk: the trial reported the following predefined primary outcomes - mortality, upper gastrointestinal bleeding, and adverse events. If the original trial protocol was available, the outcomes should be those called for in that protocol. If the trial protocol was obtained from a trial registry (e.g. [www.clinicaltrials.gov](http://www.clinicaltrials.gov)), the outcomes sought were those enumerated in the original protocol if the trial protocol was registered before or at the time that the trial was begun. If the trial protocol was registered after the trial was begun, those outcomes were not considered to be reliable.
- Unclear risk: not all predefined outcomes were reported fully, or it was unclear whether data on these outcomes were recorded or not.
- High risk: one or more predefined outcomes were not reported.

#### **Other bias**

- Low risk of bias: the trial appeared to be free of other bias domains, including vested interests that could put it at risk of bias.
- Uncertain risk of bias: the trial may or may not have been free of other domains that could put it at risk of bias.
- High risk of bias: there were other factors in the trial that could put it at risk of bias.

#### **Overall bias risk assessment**

- Low risk of bias: all domains were at low risk of bias, using the definitions described above.
- High risk of bias: one or more of the bias domains were of unclear or high risk of bias.

#### **Measures of treatment effect**

We analysed dichotomous data using risk ratios (RRs) and continuous outcomes using mean differences (MDs), both with 95% confidence intervals (CIs). For meta-analyses with statistically significant outcomes (based on the 95% CI), we calculated the number needed to treat for an additional beneficial outcome (NNTB) as  $1/\text{control risk} \times (1 - \text{RR})$ . We considered P values < 0.05 as significant.

## Unit of analysis issues

We included randomised clinical trials using a parallel group design. In multiarmed trials, we analysed separate pair-wise comparisons of the intervention of interest. We did not identify any cross-over trials. However, if such trials are identified in future updates, we will only use data from the first treatment period ([Higgins 2011](#)).

## Dealing with missing data

We extracted data on all randomised participants in order to allow intention-to-treat analyses. We undertook analyses to evaluate the influence of missing data ([Higgins 2008](#)); including, worst-case scenario analysis, and extreme worst-case and best-case scenario analyses in which we include missing outcome data as treatment failures in the intervention group and successes in the control group and vice versa ([hbg.cochrane.org/information-authors](http://hbg.cochrane.org/information-authors)).

## Assessment of heterogeneity

We evaluated heterogeneity as  $I^2$  values using the following thresholds: 0% to 40% (unimportant), 40% to 60% (moderate), 60% to 80% (substantial), and more than 80% (considerable). We included this information in [Summary of findings for the main comparison](#).

## Assessment of reporting biases

We planned to use visual inspection of funnel plots and regression analyses to evaluate reporting biases if our analysis included at least 10 trials with reported events ([Egger 1997](#); [Harbord 2006](#)). However, our review did not reach this number threshold.

## Data synthesis

### Meta-analysis

We performed our meta-analyses and regression analyses using Review Manager 5 ([Review Manager 2014](#)), and STATA version 15 ([STATA](#)). We performed random-effects and fixed-effect meta-analyses. The estimates of the random-effects and fixed-effect meta-analyses were similar for all analyses so we assumed that any small trial effects had little influence on the intervention effect estimates. In random-effects models, precision decreases with increasing heterogeneity and confidence intervals widen correspondingly. Accordingly, the random-effects model provides a more conservative estimate of the intervention effect. Thus, we only report the results of the random-effects meta-analyses.

## Subgroup analysis and investigation of heterogeneity

We planned to conduct subgroup analyses to evaluate the effect of banding in trials:

- assessed as having a low risk compared to a high risk of bias;
- involving participants with high risk compared to low risk varices;
- involving participants in whom the oesophageal varices were completely obliterated compared to those in whom they were not.

We assessed all but one of the studies at high risk of bias for the outcome, mortality ([Triantos 2005](#)). However, this trial was stopped prematurely because the rate of bleeding in the intervention group was higher than expected - at this point only 52 participants of the 214 needed for the trial to be adequately powered had been included. The trial was conducted single-blind and was only classified at low risk for mortality because mortality is robust to blinding. We did not think a subgroup analysis was warranted. We assessed all of the studies at high risk of bias for non-mortality outcomes and so we did not conduct subgroup analyses for these outcomes either. We were, however, able to analyse the differential effects of banding in people with small or large varices in one trial which provided the data separately. We also undertook post hoc subgroup analyses of trials involving participants with portal hypertension secondary to cirrhosis compared to one trial which also involved participants with non-cirrhotic portal hypertension/portal vein block. We were not able to undertake post hoc subgroup analyses of trials by the degree and severity of the underlying liver injury because of significant inter-trial heterogeneity and a lack of the necessary data.

## Sensitivity analysis

We undertook a worst-case scenario analysis and extreme worst-case and best-case scenario analyses as described in the section [Dealing with missing data](#).

We compared our GRADE assessment of imprecision with the assessments obtained from the Trial Sequential Analysis.

## Trial Sequential Analysis

We performed Trial Sequential Analysis of our primary outcomes to evaluate the risk of random error associated with sparse data and cumulative testing, and to evaluate futility ([Higgins 2008](#); [Wetterslev 2008](#)). We defined the required information size (also known as the 'diversity-adjusted required information size') as the number of participants needed to detect or reject an intervention effect based on the relative risk reduction (RRR) and the control group risk (CGR). The analyses show firm evidence if the Z-curve crosses the monitoring boundary (also known as the 'trial sequential monitoring boundary') before reaching the required information size. We used the upper CI to determine the RRR and the observed event rate in the control group. Based on the

Cochrane Hepato-Biliary Group recommendations, we set alpha to 2.5%, because of three primary outcomes, set power to 90%, and used model-based heterogeneity.

### 'Summary of findings' tables

We used [GRADEpro GDT 2015](#) to generate a 'Summary of findings' table with information about mortality, upper gastrointestinal bleeding, serious adverse events, variceal bleeding, non-serious adverse events, and quality of life. The GRADE approach appraises the certainty of a body of evidence based on the extent to which one can be confident that an estimate of effect or association reflects the item being assessed. The certainty of a body of evidence considers within-study risk of bias, indirectness of the evidence (population, intervention, control, outcomes), unexplained inconsistency (heterogeneity) of results (including problems with subgroup analyses); imprecision of results, and risk of publication bias.

We defined the levels of evidence as 'high', 'moderate', 'low', or 'very low'. These grades are defined as follows.

1. High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.
2. Moderate certainty: we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.
3. Low certainty: our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.
4. Very low certainty: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect.

## RESULTS

### Description of studies


We included six randomised clinical trials evaluating band ligation versus no intervention for primary prevention of variceal bleeding in 637 adults with cirrhosis ([Chen 1997](#); [Lay 1997](#); [Lo 1999](#); [Sarin 1996](#); [Svoboda 1999](#); [Triantos 2005](#)). One randomised clinical trial included six additional participants (9% of the total number included) with non-cirrhotic portal hypertension ([Sarin 1996](#); [Characteristics of included studies](#)).

We excluded one observational study ([Lim 2009](#)), and two randomised clinical trials ([Gameel 2005](#); [Omar 2000](#); [Characteristics of excluded studies](#)).

### Results of the search

We identified 2398 potentially relevant references in the electronic searches and 15 additional references in the manual searches. After excluding duplicates and records that were clearly irrelevant, we retrieved nine articles for detailed assessment. We excluded two randomised clinical trials because the majority of the participants had non-cirrhotic portal hypertension ([Gameel 2005](#); [Omar 2000](#)), and one further study because it was observational ([Lim 2009](#)). The remaining six randomised clinical trials fulfilled our inclusion criteria and we included them in the review ([Chen 1997](#); [Lay 1997](#); [Lo 1999](#); [Sarin 1996](#); [Svoboda 1999](#); [Triantos 2005](#)). We displayed the results of the search in a flow diagram ([Figure 1](#)), as recommended ([PRISMA 2009](#)).

**Figure 1. Study flow diagram.**



## Included studies

We included six randomised clinical trials, five published as full papers (Lay 1997; Lo 1999; Sarin 1996; Svoboda 1999; Triantos 2005), and one as an abstract (Chen 1997). One trial involving 52 participants with small or large varices was terminated prematurely because there were more upper gastrointestinal bleeding episodes in the intervention group than expected (Triantos 2005). The countries of origin were Taiwan (Chen 1997; Lay 1997; Lo 1999), India (Sarin 1996), the Czech Republic (Svoboda 1999), and Greece (Triantos 2005).

Two trials did not receive for-profit funding (Svoboda 1999; Triantos 2005). The remaining four trials did not report on funding sources (Chen 1997; Lay 1997; Lo 1999; Sarin 1996).

## Participants

Five randomised clinical trials involved 569 participants with cirrhosis and oesophageal varices that had not previously bled. The remaining randomised clinical trial, involved 68 participants with varices that had not bled, of whom six (9%) had non-cirrhotic portal hypertension or portal vein block (Sarin 1996); the trial report did not describe outcomes for participants without (or with) cirrhosis separately. The mean age of the included participants ranged from 40.6 in Sarin 1996 to 61.5 years in Triantos 2005. The proportion of men ranged from 73.5% in Triantos 2005 to 84.3% in Lo 1999. Participants with alcohol-related cirrhosis comprised 18.3% in Lay 1997 to 67.7% of cases in Svoboda 1999. Participants with Child-Pugh class C made up 11.8% in Svoboda 1999 to 42.2% of the study cohort in Triantos 2005. Five trials included participants with medium to large oesophageal varices (Chen 1997; Lay 1997; Lo 1999; Sarin 1996; Svoboda 1999), while one study (Triantos 2005), included participants with small or large oesophageal varices. Three trials used the Japanese Research Society for Portal Hypertension system of variceal classification (Lay 1997; Lo 1999; Sarin 1996); one trial used the Paquet classification system (Svoboda 1999); one trial used an open forceps and oesophageal insufflation to measure variceal diameter and classified them as small (< 5mm) or large (> 5mm); no information was provided on variceal classification in the final study (Chen 1997; Table 1). Three trials assessed the risk of variceal bleeding (Lay 1997; Lo 1999; Sarin 1996), using a standardised system (Beppu 1981).

## Interventions and comparators

All six trials evaluated band ligation of oesophageal varices (Table 2). Four randomised clinical trials used an overtube (Lay 1997; Lo 1999; Svoboda 1999; Sarin 1996), while one used a multiband

device (Triantos 2005). One study did not specify the type of ligator used (Chen 1997). In all six trials, the banding sessions were repeated until the varices were eradicated or were too small to ligate. The comparator was no intervention.

In one trial, participants in both groups were given the oral angiotensin-converting enzyme (ACE) inhibitor enalapril, and later quinapril, to reduce portal pressure (Svoboda 1999). In two studies, participants in the banding group were given sucralfate (Lay 1997; Lo 1999).

## Outcomes

All six trials reported on mortality, upper gastrointestinal bleeding, variceal bleeding and severe adverse events. Four of the six trials reported non-serious events in the band ligation group (Lo 1999; Sarin 1996; Svoboda 1999; Triantos 2005), but only one reported non-serious events in the no intervention group for comparison (Svoboda 1999). No trials reported on health-related quality of life.

Four studies reported the mean duration of follow-up which ranged from 13 months in Lay 1997 to 25 months in Svoboda 1999. Two studies reported the median duration of follow-up as 29 months in Lo 1999 and 32 months in Chen 1997.

## Excluded studies

We excluded one observational study evaluating the use of band ligation for primary prevention of variceal bleeding in people with cirrhosis who were on the waiting list for liver transplantation (Lim 2009). The study included 300 participants, of whom 258 did not have a history of variceal bleeding; 101 participants were deemed to have high risk varices and underwent primary prophylaxis. Data was retrospectively collected from patient notes and endoscopy databases. There were two reported variceal bleeds and three episodes of ulcer-related bleeds. One participant developed a mild oesophageal stricture. There were no reported deaths.

We excluded two randomised clinical trials because the majority of the included participants had portal hypertension secondary to schistosomal liver disease. The first of these trials involved 74 participants with non-alcoholic cirrhosis and/or schistosomal hepatic fibrosis and large oesophageal varices (Omar 2000). The proportion of participants without cirrhosis was not reported. Thirty-six participants were randomised to band ligation while 38 participants received no intervention. There were no bleeding-related deaths. There was no significant difference in the occurrence of variceal bleeding in the two groups during the 14-month follow-up period; one participant in the ligation group and four in the no intervention group had a bleeding episode. Complications of band ligation were minor and included variceal ulcers (44.4%),

retrosternal pain (33.3%), and low-grade fever (19.4%). No major complications were reported.

The second trial involved a three-way comparison of band ligation, sclerotherapy and no intervention in 50 participants with schistosomal portal hypertension and high risk varices, 42 (84%) of whom also had cirrhosis secondary to chronic viral hepatitis (Gameel 2005). One liver-related death occurred in the ligation group and one bleeding-related death in the control group. Two further bleeding episodes were reported in the control group. Two participants in the banding group developed oesophageal ulcera-

tion.

### Risk of bias in included studies

Based on our overall assessment, we classified one trial at low risk of bias for the assessment of mortality but at high risk of bias for the remaining outcomes (Triantos 2005), while we assessed the remaining five trials at high risk of bias for all outcomes (Chen 1997; Lay 1997; Lo 1999; Sarin 1996; Svoboda 1999; Figure 2; Figure 3).

**Figure 2. Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.**




Figure 3. Risk of bias summary: review authors' judgements about each risk of bias item for each included study.

	Random sequence generation (selection bias)	Allocation concealment (selection bias)	Blinding of participants and personnel (performance bias)	Blinding of outcome assessment (detection bias)	Incomplete outcome data (attrition bias)	Selective reporting (reporting bias)	Other bias	Overall bias assessment (mortality)	Overall bias assessment (non-mortality outcomes)
Chen 1997	?	?	-	-	?	+	+	-	-
Lay 1997	?	?	-	-	+	+	?	-	-
Lo 1999	+	?	-	-	-	+	?	-	-
Sarin 1996	?	?	-	-	+	+	+	-	-
Svoboda 1999	?	?	-	-	-	+	+	-	-
Triantos 2005	+	+	-	-	+	+	+	+	-

### Allocation

In two randomised clinical trials, investigators used a computer (Lo 1999), or table of random numbers (Triantos 2005), to generate the allocation sequence. One trial used sealed opaque envelopes, opened in a numbered sequence, to conceal allocation (Triantos 2005); one used sealed envelopes to conceal the allocation but did not stipulate if they were opaque or serially numbered (Lay 1997). The remaining trials did not describe the allocation sequence generation or allocation concealment (Chen 1997; Svoboda 1999; Sarin 1996).

### Blinding

All six randomised clinical trials were open without blinding; in none was the outcome assessment blinded.

### Incomplete outcome data

In two trials (Lay 1997; Sarin 1996), there were no missing outcome data and all the participants were included in the analyses. In one trial (Triantos 2005), two participants randomised to band ligation refused to undergo the procedure but were still included in the primary analyses but were excluded from the reporting of the complications of banding. Two trials (Lo 1999; Svoboda 1999), described losses to follow-up but excluded them from the analyses. One study did not describe participant losses (Chen 1997).

### Selective reporting

Clinically relevant outcomes were defined and reported in all six trials. We did not have access to the protocols for any of the included trials.

### Other potential sources of bias

In two of the six randomised clinical trials (Lay 1997; Lo 1999), sucralbate was given to the patients in the banding group; this is

not an effective medication for preventing upper gastrointestinal bleeding in patients with oesophageal varices but its use may be associated with improved healing of iatrogenic ulceration (Yang 1998)


### Effects of interventions

See: **Summary of findings for the main comparison** Band ligation compared to no intervention for primary prevention of upper gastrointestinal bleeding in adults with oesophageal varices All randomised clinical trials (637 participants) reported mortality (Analysis 1.1); upper gastrointestinal bleeding (Analysis 1.3); variceal bleeding (Analysis 1.7), and serious adverse events (Analysis 1.5). Non-serious adverse events were inconsistently reported and hence not amenable to meta-analysis (Table 3). None of the trials reported on health-related quality of life.

### Mortality

Band ligation had a beneficial effect on mortality when all six trials were included; overall 71 of 320 participants undergoing band ligation died compared to 129 of 317 participants in the no intervention group (risk ratio (RR) 0.55, 95% confidence interval (CI) 0.43 to 0.70;  $I^2 = 0\%$ ; Analysis 1.1). The number needed to treat to benefit (NNTB) to avoid one death is six persons. Subgroup analyses found no differences between the five trials including participants with cirrhosis and the one trial including participants with cirrhosis or non-cirrhotic portal hypertension/portal vein block (test for subgroup differences  $P = 0.78$ ; Analysis 1.1), or between the five trials involving participants with medium to large varices and the one trial involving participants with small or large varices (test for subgroup differences  $P = 0.56$ ; Analysis 1.2). Worst-case and extreme worst-case scenario analyses of all six randomised clinical trials found a beneficial effect of band ligation on mortality (Analysis 2.1), as did the Trial Sequential Analysis when setting the relative risk reduction (RRR) at 30%, control group risk (CGR) at 40%, and the heterogeneity correction at 0% (Figure 4).

**Figure 4. Trial Sequential Analysis of meta-analysis including six randomised clinical trials evaluating the effect of band ligation versus no intervention on mortality (RR 0.55, 95% CI 0.43 to 0.70; 637 participants;  $I^2 = 0\%$ ). The analysis found that the blue Z-curve crossed the trial monitoring boundary.**




### Upper gastrointestinal bleeding

Band ligation had a beneficial effect on upper gastrointestinal bleeding when all six trials were included (RR 0.44, 95% CI 0.28 to 0.72;  $I^2 = 61\%$ ; NNTB = 5 persons; [Analysis 1.3](#)). Subgroup analyses found no difference between the five trials including participants with cirrhosis and the one trial including participants with cirrhosis or non-cirrhotic portal hypertension/portal vein block (test for subgroup differences  $P = 0.22$ ; [Analysis 1.3](#)), but identified a difference between the five trials involving participants with medium to large varices where the risks were reduced, and the one

trial involving participants with small or large varices where no risk reduction was seen (test for subgroup differences  $P = 0.006$ ; [Analysis 1.4](#)).

The worst-case and extreme worst-case analyses, including all six trials showed that, on balance, band ligation reduced upper gastrointestinal bleeding ([Analysis 2.2](#)). In the Trial Sequential Analysis, including all six trials, and setting the RRR at 28%, CGR at 41%, and the heterogeneity correction at 67%, the Z-curve crossed the monitoring boundary, suggesting that band ligation has a beneficial effect on upper gastrointestinal bleeding ([Figure 5](#)).

**Figure 5. Trial Sequential Analysis including six randomised clinical trials evaluating the effect of band ligation versus no intervention on upper gastrointestinal bleeding (RR 0.44, 95% CI 0.28 to 0.72; participants = 637;  $I^2 = 61\%$ ). The analysis showed that the Z-curve crossed the trial monitoring boundary.**




### Serious adverse events

Overall, 108 of 320 participants who underwent band ligation experienced a serious adverse event compared to 201 of the 317 participants who received no intervention (RR 0.55, 95% CI 0.43 to 0.70;  $I^2 = 44\%$ ; NNTB = 4 persons; [Analysis 1.5](#)). Subgroup analyses found no difference in the five trials involving participants with cirrhosis and the one trial involving participants with cirrhosis or non-cirrhotic portal hypertension/portal vein block (test for subgroup differences ( $P = 0.28$ ; [Analysis 1.5](#)), or in the

five trials involving participants with medium to large varices and the one trial involving participants with small or large varices (test for subgroup differences  $P = 0.30$ ; [Analysis 1.6](#)). Worst-case and extreme worst-case scenario analyses including all six trials showed that band ligation reduced serious adverse events ([Analysis 2.3](#)). In the Trial Sequential Analysis, including all six trials and setting the RRR at 30%, CGR at 60%, and the heterogeneity correction at 79%, the Z-curve crossed the monitoring boundary, suggesting that band ligation has a beneficial effect on serious adverse events ([Figure 6](#)).

**Figure 6. Trial Sequential Analysis including six randomised clinical trials evaluating the effect of band ligation versus no intervention on serious adverse events (RR 0.55, 95% CI 0.43 to 0.70; 637 participants;  $I^2 = 44\%$ ). The analysis showed that the Z-curve crossed the trial monitoring boundary.**



### Variceal bleeding

Band ligation was associated with a lower risk of variceal bleeding (RR 0.43, 95% CI 0.27 to 0.69;  $I^2 = 56\%$ ; NNTB = 5 persons; [Analysis 1.7](#)). Subgroup analysis found no difference between the five trials involving participants with cirrhosis and the one trial involving participants with cirrhosis or non-cirrhotic portal hypertension/portal vein block (test for subgroup differences  $P = 0.24$ ; [Analysis 1.7](#)), but found a difference between the five trials involving participants with medium to large varices where the risks were reduced and the one trial involving participants with small or large varices where no risk reduction was seen (test for subgroup differences  $P = 0.01$ ; [Analysis 1.8](#)). The worst-case and extreme worst-case scenario analyses found a beneficial effect of band ligation on variceal bleeding ([Analysis 2.4](#)).

### Non-serious adverse events

Non-serious adverse events were reported in participants in the band ligation group in four trials ([Lo 1999](#); [Sarin 1996](#); [Svoboda 1999](#); [Triantos 2005](#)), but events in the no treatment group were only reported in one ([Svoboda 1999](#)). We were not able to under-

take a meta-analysis of these data. The non-serious adverse events reported in association with band ligation included: oesophageal ulceration, dysphagia, odynophagia, retrosternal and throat pain, heartburn and fever ([Table 3](#)). In the one study involving participants with either small or large varices ([Triantos 2005](#)), the incidence of non-serious side effects in the banding group was much higher in those with small varices in relation to ulcers: small versus large varices 30.5% versus 8.7%; heartburn 39.2% versus 17.4%.

### Health-related quality of life

None of the six included trials described health-related quality of life outcomes.

### Sensitivity analyses

We found no differences between our GRADE assessment of imprecision and that of the Trial Sequential Analysis.

### 'Summary of findings' table

We presented the results of mortality, upper gastrointestinal bleeding, serious adverse events, variceal bleeding, non-serious adverse events, and health-related quality of life in [Summary of findings for the main comparison](#). We downgraded the certainty of the evidence, for all outcomes, by one level to 'moderate' due to a high risk of bias.

## DISCUSSION

### Summary of main results

Our review found a beneficial effect of band ligation on mortality, upper gastrointestinal bleeding, including variceal bleeding, and serious adverse events. Reporting of non-serious adverse events was inconsistent and often incomplete across trials, generally unclear and potentially subject to reporting bias. No information was available on health-related quality of life. None of the trials was conducted double-blind and the certainty of the evidence was moderate due to the lack of trials with adequate bias control.

In spite of the fact that many trials were undertaken several years ago using banding devices with an overtube, the analyses found an effect on mortality. The analyses of upper gastrointestinal bleeding and variceal bleeding showed between-trial heterogeneity, which could reflect the inclusion of participants with small varices in one trial ([Triantos 2005](#)).

### Overall completeness and applicability of evidence

Our review included six randomised clinical trials, involving 637 people, published between 1996 and 2005. We were able to extract primary outcome data from all six trials.

There were inter-trial differences in the aetiology and severity of the liver disease and this may have affected outcomes. The proportion of participants with alcohol-related liver disease, in the five trials which provided details, ranged from 18.3% in [Lay 1997](#) to 67.7% in [Svoboda 1999](#). None of the trials reported on drinking behaviour during the follow-up period which is a significant determinant of outcome ([Lucey 2008](#); [Saunders 1981](#); [Xie 2014](#)). In the five trials with available data, the proportion of participants with Child's Grade C cirrhosis ranged from 11.8% in [Svoboda 1999](#) to 42.3% in [Triantos 2005](#). The risk of death within six weeks of the initial variceal haemorrhage increases with the severity of liver disease reaching 32% in people with the most severely decompensated disease ([Carbonell 2004](#)). Unfortunately, outcomes were not stratified by either the aetiology or severity of the underlying liver disease in the individual trial reports, thus precluding any form of meaningful subgroup analyses.

The classification system used to stratify variceal size also differed between trials. Of the five trials which provided this information

three used the Japanese Research Society for Portal Hypertension (JRSPH) classification system ([Lay 1997](#); [Lo 1999](#); [Sarin 1996](#)), whilst one study used the Paquet classification ([Svoboda 1999](#)). While these classifications are valuable in helping to predict the risk of variceal haemorrhage (with risk increasing with variceal size and preponderance of red signs), there have been no head-to-head comparisons between the systems ([Rigo 1992](#)). Of note, the Paquet system has not been validated since its formulation. The fifth trial classified the varices in relation to their size measured with an open forceps and their response to oesophageal insufflation ([Triantos 2005](#)); varices with a diameter of < 5 mm were classified as small while those with a diameter of > 5mm were classified as large. The authors comment on the presence or absence of red signs but do not provide information on how these were defined. The majority of participants in the included trials had varices considered to be at high risk of bleeding ([Chen 1997](#); [Lay 1997](#); [Lo 1999](#); [Sarin 1996](#); [Svoboda 1999](#)). However, in one study ([Triantos 2005](#)), 59.6% of participants had small varices likely to be at low risk of bleeding. Indeed, the incidence of upper gastrointestinal bleeding was significantly higher in participants with large rather than small varices (29% versus 3%; Fischer's exact test  $P = 0.013$ ), but the risk of bleeding did not differ between the banding and no intervention groups (large varices 57% versus 25%,  $P = 0.64$ ; small varices 7% versus 0%,  $P = 0.45$ ). This study was stopped prematurely because of the higher than expected bleeding rate in the banding group. At the time of trial cessation, however, there was no significant difference in bleeding rates in the banding (20%) and no intervention (7.4%) groups. Two of the five participants in the banding group who bled had developed portal hypertensive gastropathy following successful obliteration of their varices and this was the source of the bleeding in both; one further patient bled following insertion of the endoscope during a banding session while the final participants developed banding ulceration, although the authors still classified the bleed as variceal. Other factors, such as severity of liver disease, may have been important as this study included the highest proportion of participants with Child's Grade C cirrhosis (42%). In addition, all the participants had contraindications to or were intolerant of beta-blocker therapy. Thus, increased bleeding rates may reflect pathophysiological differences in this particular trial population. Nevertheless, the authors suggest that most of the bleeding was probably iatrogenic. Band ligation techniques and protocols varied across the trials. One study did not specify the ligation device used ([Chen 1997](#)). In four of the remaining five trials ([Lay 1997](#); [Lo 1999](#); [Sarin 1996](#); [Svoboda 1999](#)), an overtube was used in all participants or in an unspecified proportion of the study cohort. In one study ([Svoboda 1999](#)), a multiband ligation device without an overtube was used in a proportion of the patients, while a similar device was used exclusively in the latest trial ([Triantos 2005](#)). Ligation devices with an overtube are recognised to have a worse adverse effect profile and to be associated with higher rates of oesophageal injury, including varix rupture ([Wong 2000](#)). However, the authors of

the trial in which banding was undertaken, either with a ligation device with an overtube or with a multiband device without an overtube, did not comment on differences in outcomes between procedures (Svoboda 1999), and the trial that used the multiband device exclusively (Triantos 2005), did not provide data on the adverse events profile in the no intervention group.

Endoscopic variceal ligation is an operator-dependent procedure (Bohnacker 2000), although the extent to which it is so is unclear (Stiegmann 1989; Triantos 2006). Operator experience before the start of the trials varied significantly from 10 ligation sessions in Lay 1997 and Lo 1999 to  $\geq 300$  sessions of endoscopic interventions in Svoboda 1999. Operator experience was not described in the remaining two trials (Chen 1997; Sarin 1996). However, there were no significant differences in the frequency of serious adverse events in the trials with the less experienced operators at 40% in Lay 1997 and 39% in Lo 1999, and the trial with the most experienced operators at 42% (Svoboda 1999). Likewise there did not appear to be any significant difference in the frequency of non-serious adverse events between trials employing less experienced operators in Lo 1999 or more experienced operators in Svoboda 1999. (See Table 3).

The number of bands applied per varix, the maximum number of bands applied per session and the number of sessions undertaken were inconsistently reported, and where reported, differed between trials (Table 2). In the majority of trials, one to three bands were applied to each varix or variceal column at each session; the maximum number of bands applied was only specified in two studies as six in Svoboda 1999 and 10 in Lay 1997. Sessions were undertaken at varying time intervals, ranging from every seven to 10 days in Sarin 1996 to every three weeks in Lay 1997 and Lo 1999. Banding was performed until varices were eradicated or were too small to ligate in all six trials. This endpoint was reached in two trials (Lay 1997; Sarin 1996). Eradication rates ranged from 80% in Triantos 2005 to 89% in Chen 1997 in the remaining four trials (Chen 1997; Lo 1999; Svoboda 1999; Triantos 2005). The mean number of sessions required to reach this endpoint ranged from two in Triantos 2005 to 4.8 in Svoboda 1999. The differences in success rates for variceal obliteration may reflect differences in operator proficiency, ligation protocol or participant willingness to comply (Table 2). Follow-up endoscopy was undertaken every three months after the finish of the band ligation in the four trials which provided this information (Lay 1997; Lo 1999; Sarin 1996; Svoboda 1999).

The duration of follow-up varied between trials from a mean of 13 months in Lay 1997 to a median of 32 months in Chen 1997. As most episodes of variceal haemorrhage occur within the first two years (Burroughs 1986), follow-up schedules shorter than this may underestimate the effect size of any benefit afforded by ligation prophylaxis.

Sucralfate was given to participants undergoing band ligation in two trials (Lay 1997; Lo 1999). The use of sucralfate is associated with improved oesophageal ulcer healing in patients undergoing

endoscopic variceal sclerotherapy, but there is no evidence that it affects bleeding rates (Yang 1998). There are no trials on the use of sucralfate in people undergoing variceal band ligation so we included these two trials as the use of sucralfate was unlikely to affect any of our primary outcomes.

We planned to undertake a series of subgroup analyses. However, none was possible. Thus, apart from one trial which we classified at low risk of bias for mortality (Triantos 2005), we otherwise assessed the included trials at high risk of bias, so we could not explore outcomes in relation to the stratification of risk bias. We were also unable to perform subgroup analyses based on the characteristics of the varices in relation to their risk of bleeding as all but one of the trials included patients with medium to large varices judged to be at high risk. We were, however, able to analyse the differential effects of banding in people with small or large varices in one trial (Triantos 2005). This showed that although the incidence of upper gastrointestinal bleeding was significantly higher in participants with large rather than small varices, the risk of bleeding did not differ between the banding and no treatment groups. However, this study was terminated prematurely because the number of bleeding episodes in the banding group was higher than expected. Finally, we were unable to undertake subgroup analyses based on the completeness of the variceal obliteration as insufficient data were provided within trials and because the variceal recurrence rates were high, ranging from 21.8% in Lo 1999 to 42.0% in Lay 1997, nor were we able to undertake subgroup analyses based on the aetiology and severity of the liver disease.

This review included participants with portal hypertension secondary to chronic liver disease. We excluded studies in people with portal hypertension associated with schistosomiasis, portal/splenic vein thrombosis, Budd-Chiari syndrome and other rarer conditions of pre- or postsinusoidal block. However, one included trial contained a small number of participants, amounting to < 10% of the total, with non-cirrhotic portal hypertension/portal vein block (Sarin 1996). We undertook a post hoc subgroup analyses of trials involving participants with portal hypertension secondary to cirrhosis compared to this one trial and found no essential differences in our primary outcomes. The Baveno guidelines state that there are insufficient data on whether beta-blockers or endoscopic therapy should be preferred for primary prophylaxis in people with extrahepatic portal vein block/idiopathic portal hypertension and suggest that the guidelines for cirrhosis should be applied (Baveno VI 2015).

This review showed that when used for primary prophylaxis for upper gastrointestinal bleeding in patients with cirrhosis, who have not bled previously, band ligation has beneficial effects on mortality, upper gastrointestinal bleeding, including variceal bleeding, and serious adverse events compared to no intervention. Current recommendation stipulates that the benefit of ligation extends only to the treatment of medium to large varices.

## Certainty of the evidence

The main reason for downgrading the evidence in this review is bias. As recommended, we combined the individual bias domains in an overall assessment ([hbg.cochrane.org/information-authors](http://hbg.cochrane.org/information-authors)). We identified potential biases in all of the included trials. We defined mortality, but not serious adverse events, as an outcome that is robust to performance and detection bias (Savović 2012a; Savović 2012b). This decision can be questioned, as lack of blinding is not likely to influence the assessment of events such as upper gastrointestinal bleeding.

Several trials lacked information about allocation methods, which is one of the most important bias domains. Although, none reported clear differences between intervention and control groups, we cannot exclude the possibility of selection bias. In addition, all trials were open without blinding and hence were at high risk of bias for this domain. Only three trials provided full outcome data and included all participants in their analyses and we consequently classified them at low risk for attrition bias (Lay 1997; Sarin 1996; Triantos 2005); two trials did not account for all participants and thus had a high risk for attrition bias (Lo 1999; Svoboda 1999); the risk in the remaining trial was unclear (Chen 1997). All trials reported outcome data for all of the primary outcome measures and so were at low risk for reporting bias. One trial was at low risk of bias for mortality (Triantos 2005), while the remaining trials were at high risk of bias for this overall domain. As none of the trials were double-blind they were all at high risk of bias in the assessment of bleeding and serious adverse events.

We registered for-profit funding ([hbg.cochrane.org/information-authors](http://hbg.cochrane.org/information-authors)). Two trials were not in receipt of this type of funding (Svoboda 1999; Triantos 2005), but the remaining four trials did not report on funding sources. Thus, we were not able to undertake a post hoc subgroup analysis based on for-profit funding.

We found little heterogeneity when assessing the trials clinically. The included participants had cirrhosis, mainly due to alcohol or viral hepatitis and the clinical settings were similar in all six trials. The publication year varied, which indicates that the collateral interventions may have varied, e.g. in terms of antibiotic use and the type of banding. On the other hand, our analyses showed little to moderate between-trial heterogeneity.

Only one trial described a sample size calculation (Triantos 2005); the authors of this trial determined that they would need to enrol 214 participants and observe 37 events for adequate power. However, the trial was stopped after the inclusion of 52 participants because the number of bleeding events in the band ligation group was double that expected, although the difference in bleeding rates between the band ligation and no treatment groups was not significant at that time (20% versus 7.4%). Considering the sample size calculation in the Triantos trial, it is possible that the trials included in our review were underpowered. Nevertheless, both the pair-wise and the Trial Sequential Analysis still found a beneficial effect of band ligation on outcomes compared to no intervention.

## Potential biases in the review process

We undertook the review based on current recommendations for bias control ([hbg.cochrane.org/information-authors](http://hbg.cochrane.org/information-authors); Higgins 2017). We attempted to minimise possible selection bias (Page 2014), by using a comprehensive search strategy; we combined searches in electronic databases with handsearches of the biographies of identified trials and the conference proceedings and abstract books from relevant national and international society meetings. We consider it unlikely that we failed to identify any published trials.

## Agreements and disagreements with other studies or reviews

The present review includes five randomised clinical trials published as full papers (Lay 1997; Lo 1999; Sarin 1996; Svoboda 1999; Triantos 2005), and one published abstract (Chen 1997), reporting the use of band ligation for primary prophylaxis of upper gastrointestinal bleeding compared to no treatment in participants with cirrhosis. We excluded two primary prophylaxis trials, both published in abstract form because the majority of the included participants had non-cirrhotic portal hypertension (Gameel 2005; Omar 2000).

We identified five previous meta-analyses of trials of band ligation compared to no treatment in patients with oesophageal varices that had not bled. Three were published as full papers (Imperiale 2001; NICE 2016; Vlachogiannakos 2000); one was included as part of the discussion in an original randomised clinical trial published in full (Triantos 2005), and one was published as an abstract (Bedi 2000). They all include varying combinations of the trials we included or excluded; none of the previous meta-analyses included trials we had not identified or considered.

The first of the meta-analyses (Bedi 2000), included three randomised clinical trials and one abstract. No further details of the included trials are provided, not even the names of the first authors. Pooled results from the three trials published as full papers showed that use of band ligation had a favourable effect on all-cause mortality (odds ratio (OR) 0.41, 95% confidence interval (CI) 0.25 to 0.65), bleeding-related mortality (OR 0.25, 95% CI 0.12 to 0.56), and variceal bleeding (OR 0.25, 95% CI 0.15 to 0.42). Including data from the trial reported in abstract form did not significantly affect the results of the meta-analyses.

The second meta-analysis (Vlachogiannakos 2000), included four trials published as full papers (Lay 1997; Lo 1999; Sarin 1996; Svoboda 1999), and two published as abstracts (Chen 1997; Gameel 2005). It found that band ligation reduced both the risk of mortality (pooled OR 2.44, 95% CI 1.7 to 3.51) and of the first variceal bleed (pooled OR 4.26, 95% CI 2.85 to 6.37).

The third meta-analysis (Imperiale 2001), included three trials published as full papers (Lay 1997; Lo 1999; Sarin 1996), and two published as abstracts (Chen 1997; Gameel 2005), and found

that, compared to no treatment, band ligation reduces all-cause mortality (risk ratio (RR) 0.55, 95% CI 0.43 to 0.71), bleeding-related mortality (RR 0.20, 95% CI 0.11 to 0.39), and first variceal bleed (RR 0.35, 95% CI 0.26 to 0.50).

The fourth meta-analysis was included in the discussion of an original publication of this topic (Triantos 2005); it was intended to place the findings of this study, which was stopped prematurely because the rate of bleeding in the band ligation group was greater than expected, in context with the findings in the other trials conducted to date. The authors included five trial papers published in full, including their own (Lay 1997; Lo 1999; Sarin 1996; Svoboda 1999; Triantos 2005), and three trials published in abstract form (Chen 1997; Gameel 2005; Omar 2000; ). They concluded that, in comparison to no treatment, band ligation reduces the risk of death (OR 0.43, 95% CI 0.30 to 0.60) and of the first variceal bleed (OR 0.31, 95% CI 0.17 to 0.53). Of note the findings in one of the trials included in this meta-analysis (Gameel 2005), are reported incorrectly as showing no deaths in the no treatment group.

The final meta-analysis (NICE 2016), included five trials published as full papers (Lay 1997; Lo 1999; Sarin 1996; Svoboda 1999; Triantos 2005). The authors undertook time-to-event analyses using the data available from two studies with 253 participants (Lay 1997; Lo 1999), and found moderate-certainty evidence of a clinically important benefit of band ligation, over no intervention, on survival and variceal bleeding in people with medium to large varices. They found very low-certainty evidence that band ligation was associated with a reduction in overall mortality compared to no treatment (RR 0.57, 95% CI 0.33 to 0.97; 2 trials, 170 participants) and very low-certainty evidence of a benefit of band ligation on upper gastrointestinal bleeding (RR 0.49, 95% CI 0.31 to 0.76; 5 trials, 444 participants). Although they include all five trials in the analysis of upper gastrointestinal bleeding, they only included two studies in their analysis of overall mortality (Sarin 1996; Svoboda 1999); this is unexplained, as mortality data were extractable from all five of the included trials.

The majority of the previous meta-analyses included one or more of the trials we excluded because the majority of the participants had non-cirrhotic portal hypertension (Gameel 2005; Omar 2000). In addition, whereas we used outcome and complication data from the actual trial period, two meta-analyses (Triantos 2005; Vlachogiannakos 2000), used the 2-year cumulative mortality and bleeding rates provided in one included study (Lay 1997), while another (NICE 2016), used the time-to-event data for mortality and variceal bleeding provided in two included studies (Lay 1997; Lo 1999). Nevertheless, despite these participant and procedural differences, the results of our meta-analysis are in accord with the findings in earlier meta-analyses that, compared to no treatment, band ligation reduces the risk of death and of serious adverse events, including variceal bleeding, in people with oesophageal varices who have not previously bled.

## AUTHORS' CONCLUSIONS

### Implications for practice

This review includes randomised clinical trials evaluating the use of band ligation for the primary prevention of variceal bleeding. Our analyses has found evidence that band ligation reduces mortality, upper gastrointestinal bleeding, including variceal bleeding, and serious adverse events, when compared to no intervention. However, there were limitations in the amount and certainty of the evidence, little information about non-serious adverse events, and no data concerning health-related quality of life. Nevertheless, band ligation is recommended as one alternative treatment for primary prevention of variceal bleeding in people with medium to large varices, and is used widely in clinical practice, particularly where treatment with non-selective beta-blockers is either contraindicated or not tolerated.

### Implications for research

Variceal bleeding is a medical emergency associated with a mortality rate which, in spite of recent progress, is still of the order of 10% to 20% at six weeks (Carbonell 2004). Guidelines have been formulated for the management of portal hypertension in a series of 'Baveno' consensus workshops undertaken at intervals from 1986; the latest of these, Baveno VI, was published in 2015 (Baveno VI 2015). The National Institute for Health and Care Excellence (NICE) has also provided guidance on aspects of the assessment and management of portal hypertension relevant to this review (NICE 2016).

Five of the trials included in the present review were undertaken between 1996 and 1999 prior to the publication of the recommendations of the Baveno III to VI consensus workshops; the fifth trial was published in 2005 and hence prior to Baveno V and VI. All of the trials were performed before publication of the NICE Guidelines.

According to both sets of guidelines, endoscopic band ligation is not recommended as a treatment option for people with small varices (Baveno VI 2015; NICE 2016). People with small varices without signs of increased risk may be treated with non-selective beta-blockers to prevent bleeding; those with red wale marks or with severely decompensated cirrhosis are at increased risk of bleeding and should be treated with non-selective beta-blockers (Baveno VI 2015). The Baveno consensus recommends that people with medium to large varices should be treated with a non-selective beta-blocker or endoscopic band ligation for the prevention of the first variceal bleed (Baveno VI 2015).

Given the substantial mortality associated with variceal bleeding and the fact that band ligation is now an established and recommended treatment for primary prophylaxis of variceal bleeding in people with cirrhosis and medium to large varices, we do not

believe that further trials of band ligation compared to no intervention could be justified on ethical grounds.

## ACKNOWLEDGEMENTS

We thank Sarah Louise Klingenberg, Information Specialist in the Cochrane Hepato-Biliary Group, for her help with the search strategies and the electronic searches.

This review did not receive funding support.

**Cochrane Review Group funding acknowledgement:** The Danish State is the largest single funder of the Cochrane Hepato-Bil-

itary Group through its investment in the Copenhagen Trial Unit, Centre for Clinical Intervention Research, Rigshospitalet, Copenhagen University Hospital, Denmark.

**Disclaimer:** The views and opinions expressed in this review are those of the authors and do not necessarily reflect those of the Danish State or the Copenhagen Trial Unit.

Peer Reviewers: Giovanni Casazza, Italy; Gautam Mehta, UK; Emmanouil Tsochatzis, UK

Contact Editor: Agostino Colli, Italy

Sign-off Editor: Agostini Colli, Italy

## REFERENCES

### References to studies included in this review

- Chen 1997** *{published data only}*  
Chen CY, Chen CY, Chang TT. Prophylactic endoscopic variceal ligation (EVL) for esophageal varices. *Gastroenterology* 1997;**112**:A1240.
- Lay 1997** *{published data only}*  
Lay CS, Tsai YT, Teg CY, Shyu WS, Guo WS, Wu KL, et al. Endoscopic variceal ligation in prophylaxis of first variceal bleeding in cirrhotic patients with high-risk esophageal varices. *Hepatology* 1997;**25**(6):1346–50. DOI: 10.1002/hep.510250608; PUBMED: 9185751
- Lo 1999** *{published data only}*  
Lo GH, Lai KH, Cheng JS, Lin CK, Hsu PI, Chiang HT. Prophylactic banding ligation of high-risk esophageal varices in patients with cirrhosis: a prospective, randomized trial. *Journal of Hepatology* 1999;**31**(3):451–6. PUBMED: 10488703]
- Sarin 1996** *{published data only}*  
Sarin SK, Guptan RK, Jain AK, Sundaram KR. A randomized controlled trial of endoscopic variceal band ligation for primary prophylaxis of variceal bleeding. *European Journal of Gastroenterology & Hepatology* 1996;**8**(4):337–42. PUBMED: 8781902]
- Svoboda 1999** *{published data only}*  
Svoboda B, Kantorova I, Ochmann J, Kozumplik L, Marsova J. A prospective randomized controlled trial of sclerotherapy vs ligation in the prophylactic treatment of high-risk esophageal varices. *Surgical Endoscopy* 1999;**13**(6):580–4. PUBMED: 10347295]
- Triantos 2005** *{published data only}*  
Triantos C, Vlachogiannakos J, Armonis A, Saveriadis A, Kougioumtzian A, Leandro G, et al. Primary prophylaxis of variceal bleeding in cirrhotics unable to take beta-blockers: a randomized trial of ligation. *Alimentary Pharmacology & Therapeutics* 2005;**21**(12):1435–43. DOI: 10.1111/j.1365-2036.2005.02457.x; PUBMED: 15948810

### References to studies excluded from this review

- Gameel 2005** *{published data only}*  
Gameel K, Waked I, Saleh S, Sallam M, Abdel-Fattah S. Prophylactic endoscopic variceal band ligation (EVL) versus sclerotherapy (ES) for the prevention of variceal bleeding: an interim report of a prospective randomized controlled trial in schistosomal portal hypertension. *Hepatology* 1995;**22**(4):A251.
- Lim 2009** *{published data only}*  
Lim EJ, Gow PJ, Angus PW. Endoscopic variceal ligation for primary prophylaxis of esophageal variceal hemorrhage in pre-liver transplant patients. *Liver Transplantation* 2009;**15**(11):1508–13. DOI: 10.1002/lt.21857; PUBMED: 19877221
- Omar 2000** *{published data only}*  
Omar MM, Attia MH, Mostafa IM. Prophylactic band ligation to prevent first bleeding from large esophageal varices. *Gastrointestinal Endoscopy* 2000;**51**(4):AB122.

### Additional references

- Albillos 2007**  
Albillos A, Banares R, Gonzalez M, Ripoll C, Gonzalez R, Catalina MV, et al. Value of the hepatic venous pressure gradient to monitor drug therapy for portal hypertension: a meta-analysis. *American Journal of Gastroenterology* 2007;**102**(5):1116–26. DOI: 10.1111/j.1572-0241.2007.01191.x; PUBMED: 17391317
- ASGE 2008**  
ASGE Technology Committee, Liu J, Petersen BT, Tierney WM, Chuttani R, Disario JA, Coffie JM, et al. Endoscopic banding devices. *Gastrointestinal Endoscopy* 2008;**68**(2):217–21. DOI: 10.1016/j.gie.2008.03.1121; PUBMED: 18656592

- Asrani 2013**  
Asrani SK, Kamath PS. Natural history of cirrhosis. *Current Gastroenterology Reports* 2013;**15**(2):308. DOI: 10.1007/s11894-012-0308-y; PUBMED: 23314828
- Baveno VI 2015**  
de Franchis R. Expanding consensus in portal hypertension Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension. *Journal of Hepatology* 2015;**63**(3):743–52. DOI: 10.1016/j.jhep.2015.05.022; PUBMED: 26047908
- Bedi 2000**  
Bedi A, Macintosh D, Fardy J. A meta-analysis of endoscopic variceal ligation for primary prophylaxis of esophageal varices. *American Journal of Gastroenterology* 2000;**95**:2413.
- Beppu 1981**  
Beppu K, Inokuchi K, Koyanagi N, Nakayama S, Sakata H, Kitano S, et al. Prediction of variceal hemorrhage by esophageal endoscopy. *Gastrointestinal Endoscopy* 1981;**4**: 213–8. [PUBMED: 6975734]
- Bohnacker 2000**  
Bohnacker S, Sriram PV, Soehendra N. The role of endoscopic therapy in the treatment of bleeding varices. *Best Practice & Research Clinical Gastroenterology* 2000;**14** (3):477–94. DOI: 10.1053/bega.2000.0092; PUBMED: 10952810
- Bosch 2003**  
Bosch J, Garcia-Pagan JC. Prevention of variceal rebleeding. *Lancet* 2003;**361**(9361):952–4. DOI: 10.1016/S0140-6736(03)12778-X; PUBMED: 12648985
- Bosch 2015**  
Bosch J, Groszmann RJ, Shah VH. Evolution in the understanding of the pathophysiological basis of portal hypertension: how changes in paradigm are leading to successful new treatments. *Journal of Hepatology* 2015;**62** (Suppl 1):S121–30. DOI: 10.1016/j.jhep.2015.01.003; PMC 4519833; PUBMED: 25920081
- Brunner 2017**  
Brunner F, Berzigotti A, Bosch J. Prevention and treatment of variceal haemorrhage in 2017. *Liver International* 2017; **37**(Suppl 1):104–15. DOI: 10.1111/liv.13277; PUBMED: 28052623
- Burroughs 1986**  
Burroughs AK, D'Heygere F, McIntyre N. Pitfalls in studies of prophylactic therapy for variceal bleeding in cirrhotics. *Hepatology* 1986;**6**(6):1407–13. [PUBMED: 3491780]
- Carbonell 2004**  
Carbonell N, Pauwels A, Serfaty L, Fourdan O, Lévy VG, Poupon R. Improved survival after variceal bleeding in patients with cirrhosis over the past two decades. *Hepatology* 2004;**40**(3):652–9. DOI: 10.1002/hep.20339; PUBMED: 15349904
- Chalasani 2003**  
Chalasani N, Kahi C, Francois F, Pinto A, Marathe A, Bini EJ, et al. Improved patient survival after acute variceal bleeding: a multicenter, cohort study. *American Journal of Gastroenterology* 2003;**98**(3):653–9. [PUBMED: 12650802]
- Collins 2001**  
Collins D, Worthley LI. Acute gastrointestinal bleeding: part II. *Critical Care and Resuscitation* 2001;**3**(2):117–24. [PUBMED: 16610996]
- D'Amico 1995**  
D'Amico G, Pagliaro L, Bosch J. The treatment of portal hypertension: a meta-analytic review. *Hepatology* 1995;**22** (1):332–54. [PUBMED: 7601427]
- D'Amico 1999**  
D'Amico G, Pagliaro L, Bosch J. Pharmacological treatment of portal hypertension: an evidence-based approach. *Seminars in Liver Disease* 1999;**19**(4):475–505. DOI: 10.1055/s-2007-1007133; PUBMED: 10643630
- D'Amico 2003**  
D'Amico G, De Franchis R. Upper digestive bleeding in cirrhosis. Post-therapeutic outcome and prognostic indicators. *Hepatology* 2003;**38**(3):599–612. DOI: 10.1053/jhep.2003.50385; PUBMED: 12939586
- D'Amico 2007**  
D'Amico G, Garcia-Pagan JC, Luca A, Bosch J. Hepatic vein pressure gradient reduction and prevention of variceal bleeding in cirrhosis: a systematic review. *Gastroenterology* 2007;**131**(5):1611–24. DOI: 10.1053/j.gastro.2006.09.013; PUBMED: 17101332
- De Lisi 2010**  
De Lisi S, Peralta S, Arini A, Simone F, Craxi A. Oesophagogastroduodenoscopy in patients with cirrhosis: extending the range of detection beyond portal hypertension. *Digestive Liver Disease* 2011;**43**(1):48–53. DOI: 10.1016/j.dld.2010.04.004; PUBMED: 20471338
- Egger 1997**  
Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. *BMJ (Clinical Research Ed.)* 1997;**315**(7109):629–34. [PUBMED: 9310563]
- Garcia-Tsao 2007**  
Garcia-Tsao G, Sanyal AJ, Grace ND, Carey W, Practice Guidelines Committee of the American Association for the Study of Liver Diseases. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. *Hepatology* 2007;**46**(3):922–38. DOI: 10.1002/hep.21907; PUBMED: 17879356
- Garcia-Tsao 2008**  
Garcia-Tsao G, Bosch J, Groszmann RJ. Portal hypertension and variceal bleeding - unresolved issues. Summary of an American Association for the study of liver diseases and European Association for the study of the liver single-topic conference. *Hepatology* 2008;**47**(5):1764–72. DOI: 10.1002/hep.22273; PUBMED: 18435460
- García-Pagán 1990**  
García-Pagán JC, Navasa M, Bosch J, Bru C, Pizcueta P, Rodés J. Enhancement of portal pressure reduction by the association of isosorbide-5-mononitrate to propranolol

administration in patients with cirrhosis. *Hepatology* 1990; **11**(2):230–8. [PUBMED: 2307401]

#### **Gluud 2007**

Gluud LL, Klingenberg S, Nikolova D, Gluud C. Banding ligation versus beta-blockers as primary prophylaxis in esophageal varices: systematic review of randomized trials. *American Journal of Gastroenterology* 2007;**102**(12):2842–8. DOI: 10.1111/j.1572-0241.2007.01564.x; PUBMED: 18042114

#### **Gluud 2012**

Gluud LL, Krag A. Banding ligation versus beta-blockers for primary prevention in oesophageal varices in adults. *Cochrane Database of Systematic Reviews* 2012, Issue 8. DOI: 10.1002/14651858.CD004544.pub2; PUBMED: 22895942

#### **GRADEpro GDT 2015 [Computer program]**

McMaster University (developed by Evidence Prime). GRADEpro GDT. Version accessed 26 February 2019. Hamilton (ON): McMaster University (developed by Evidence Prime), 2015.

#### **Groszmann 2005**

Groszmann RJ, Garcia-Tsao G, Bosch J, Grace ND, Burroughs AK, Planas R, et al. Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis. *New England Journal of Medicine* 2005;**353**(21):2254–61. DOI: 10.1056/NEJMoa044456; PUBMED: 16306522

#### **Harbord 2006**

Harbord RM, Egger M, Sterne JA. A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints. *Statistics in Medicine* 2006;**25**(20): 3443–57. DOI: 10.1002/sim.2380; PUBMED: 16345038

#### **Higgins 2008**

Higgins J, White IR, Wood AM. Imputation methods for missing outcome data in meta-analysis of clinical trials. *Clinical Trials* 2008;**5**(3):225–39. DOI: 10.1177/1740774508091600; PUBMED: 18559412

#### **Higgins 2011**

Higgins JP, Green S, editor(s). *Cochrane Handbook for Systematic Reviews of Interventions* Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from [handbook.cochrane.org](http://handbook.cochrane.org).

#### **Higgins 2017**

Higgins JP, Altman DG, Sterne JA, editor(s). Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Churchill R, Chandler J, Cumpston MS, editor(s). *Cochrane Handbook for Systematic Reviews of Interventions* version 5.2.0 (updated June 2017). The Cochrane Collaboration, 2017. Available from: [www.training.cochrane.org/handbook](http://www.training.cochrane.org/handbook).

#### **Hobolth 2010**

Hobolth L, Krag A, Bendtsen F. The recent reduction in mortality from bleeding oesophageal varices is primarily observed from days 1 to 5. *Liver International* 2010;**30**(3):455–62. DOI: 10.1111/j.1478-3231.2009.02169.x; PUBMED: 19968778

#### **ICH-GCP 1997**

International Conference on Harmonisation Expert Working Group. *International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH harmonised tripartite guideline. Guideline for good clinical practice CFR & ICH Guidelines*. Vol. 1, Philadelphia (PA): Barnett International/PAREXEL, 1997.

#### **Imperiale 2001**

Imperiale TF, Chalasani N. A meta-analysis of endoscopic variceal ligation for primary prophylaxis of esophageal variceal bleeding. *Hepatology* 2001;**33**(4):802–7. DOI: 10.1053/jhep.2001.23054; PUBMED: 11283842

#### **Inokuchi 1980**

Inokuchi K, on behalf of the Japanese Research Society for Portal Hypertension. The general rules for recording endoscopic findings on esophageal varices. *Japanese Journal of Surgery* 1980;**10**(1):84–7.

#### **Iwakiri 2014**

Iwakiri Y, Shah V, Rockey DC. Vascular pathobiology in chronic liver disease and cirrhosis - current status and future directions. *Journal of Hepatology* 2014;**61**(4):912–24. DOI: 10.1016/j.jhep.2014.05.047; PUBMED: 24911462

#### **Kovalak 2007**

Kovalak M, Lake J, Mattek N, Eisen G, Lieberman D, Zaman A. Endoscopic screening for varices in cirrhotic patients: data from a national endoscopic database. *Gastrointestinal Endoscopy* 2007;**65**(1):82–8. DOI: 10.1016/j.gie.2006.08.023; PUBMED: 17185084

#### **Lebrech 1981**

Lebrech D, Nouel O, Bernuau J, Bouygues M, Rueff B, Benhamou JP. Propranolol in prevention of recurrent gastrointestinal bleeding in cirrhotic patients. *Lancet* 1981; **1**(8226):920–1. [PUBMED: 6112329]

#### **Longacre 2008**

Longacre AV, Imaeda A, Garcia-Tsao G, Fraenkel L. A pilot project examining the predicted preferences of patients and physicians in the primary prophylaxis of variceal hemorrhage. *Hepatology* 2008;**47**(1):169–76. DOI: 10.1002/hep.21945; PUBMED: 17935182

#### **Lucey 2008**

Lucey MR, Connor JT, Boyer TD, Henderson JM, Rikkers LF, DIVERT Study Group. Alcohol consumption by cirrhotic subjects: patterns of use and effects on liver function. *American Journal of Gastroenterology* 2008;**103**(7):1698–706. DOI: 10.1111/j.1572-0241.2008.01837.x; PUBMED: 18494835

#### **MECIR 2018**

Higgins JP, Lasserson T, Chandler J, Tovey D, Churchill R. *Methodological Expectations of Cochrane Intervention Reviews -Version 1.06*. [community.cochrane.org/mecir-manual](http://community.cochrane.org/mecir-manual) 2018.

#### **Merli 2003**

Merli M, Nicolini G, Angeloni S, Rinaldi V, De Santis A, Merkel C, et al. Incidence and natural history of small esophageal varices in cirrhotic patients. *Journal of Hepatology* 2003;**38**(3):266–72. [PUBMED: 12586291]

**Moreau 2006**

Moreau R, Lebrec D. Molecular and structural basis of portal hypertension. *Clinics in Liver Disease* 2006;**10**(3): 445–57. DOI: 10.1016/j.cld.2006.08.011; PUBMED: 17162222

**NICE 2016**

National Institute for Health and Care Excellence. Cirrhosis in over 16s: assessment and management. www.nice.org.uk/guidance/ng50 (accessed 26 February 2019).

**NIEC 1988**

The North Italian Endoscopic Club for the Study and Treatment of Esophageal Varices. Prediction of the first variceal hemorrhage in patients with cirrhosis of the liver and esophageal varices. A prospective multicenter study. *New England Journal of Medicine* 1988;**319**(15):983–9. DOI: 10.1056/NEJM198810133191505; PUBMED: 3262200

**Page 2014**

Page MJ, McKenzie JE, Kirkham J, Dwan K, Kramer S, Green S, et al. Bias due to selective inclusion and reporting of outcomes and analyses in systematic reviews of randomised trials of healthcare interventions. *Cochrane Database of Systematic Reviews* 2014, Issue 10. DOI: 10.1002/14651858.MR000035.pub2; MROOOO35

**Paquet 1978**

Paquet KJ, Oberhammer E. Sclerotherapy of bleeding oesophageal varices by means of endoscopy. *Endoscopy* 1978;**10**(1):7–12. DOI: 10.1055/s-0028-1098252; PUBMED: 75791

**Poynard 1991**

Poynard T, Calès P, Pasta L, Ideo G, Pascal JP, Pagliaro L, et al. Beta-adrenergic-antagonist drugs in the prevention of gastrointestinal bleeding in patients with cirrhosis and esophageal varices. An analysis of data and prognostic factors in 589 patients from four randomized clinical trials. Franco-Italian Multicenter Study Group. *New England Journal of Medicine* 1991;**324**(22):1532–8. DOI: 10.1056/NEJM199105303242202; PUBMED: 1674104

**PRISMA 2009**

Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *BMJ (Clinical Research Ed.)* 2009;**339**:b2535. DOI: 10.1136/bmj.b2535; PMC 2714657; PUBMED: 19622551

**Reiberger 2013**

Reiberger T, Ulbrich G, Ferlitsch A, Payer BA, Schwabl P, Pinter M, et al. Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol. *Gut* 2013;**62**(11):1634–41. DOI: 10.1136/gutjnl-2012-304038; CRSREF: 9368813; PUBMED: 23250049

**Review Manager 2014 [Computer program]**

Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.

**Rigo 1992**

Rigo GP, Merighi A, Chahin NJ, Mastronardi M, Codeluppi PL, Ferrari A, et al. A prospective study of the ability of three endoscopic classifications to predict hemorrhage from esophageal varices. *Gastrointestinal Endoscopy* 1992;**38**(4): 425–9. [PUBMED: 1511815]

**Ripoli 2007**

Ripoll C, Groszmann R, Garcia-Tsao G, Grace N, Burroughs A, Planas R, et al. Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis. *Gastroenterology* 2007;**133**(2): 481–8. DOI: 10.1053/j.gastro.2007.05.024; PUBMED: 17681169

**Royle 2003**

Royle P, Milne R. Literature searching for randomized controlled trials used in Cochrane reviews: rapid versus exhaustive searches. *International Journal of Technology Assessment in Health Care* 2003;**19**(4):591–603. [PUBMED: 15095765]

**Saunders 1981**

Saunders JB, Walters JR, Davies AP, Paton A. A 20-year prospective study of cirrhosis. *British Medical Journal (Clinical Research Ed.)* 1981;**282**(6260):263–6.

**Savović 2012a**

Savović J, Jones H, Altman D, Harris R, Juni P, Pildal J, et al. Influence of reported study design characteristics on intervention effect estimates from randomised controlled trials: combined analysis of meta-epidemiological studies. *Health Technology Assessment* 2012;**16**(35):1–82. DOI: 10.3310/hta16350; PUBMED: 22989478

**Savović 2012b**

Savović J, Jones HE, Altman DG, Harris RJ, Juni P, Pildal J, et al. Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. *Annals of Internal Medicine* 2012;**157**(6):429–38. DOI: 10.7326/0003-4819-157-6-201209180-00537; PUBMED: 22945832

**Schmitz 2001**

Schmitz RJ, Sharma P, Badr AS, Qamar MT, Weston AP. Incidence and management of esophageal stricture formation, ulcer bleeding, perforation, and massive hematoma formation from sclerotherapy versus band ligation. *American Journal of Gastroenterology* 2001;**96**(2):437–41. DOI: 10.1111/j.1572-0241.2001.03460.x; PUBMED: 11232687

**STATA [Computer program]**

Stata Corp, Texas, USA. Stata 14. Stata Corp, Texas, USA, 2007.

**Stiegmann 1989**

Stiegmann GV, Goff JS, Sun JH, Davis D, Bozdech J. Endoscopic variceal ligation: an alternative to sclerotherapy. *Gastrointestinal Endoscopy* 1989;**35**(5):431–4. [PUBMED: 2792677]

**Thabut 2007**

Thabut D, Hammer M, Cai Y, Carbonell N. Cost of treatment of oesophageal variceal bleeding in patients

with cirrhosis in France: results of a French survey. *European Journal of Gastroenterology & Hepatology* 2007;**19**(8):679–86. DOI: 10.1097/MEG.0b013e3281bcb784; PUBMED: 17625438

**Triantos 2006**

Triantos C, Vlachogiannakos J, Manolakopoulos S, Burroughs A, Avgerinos A. Is banding ligation for primary prevention of variceal bleeding as effective as beta-blockers, and is it safe?. *Hepatology* 2006;**43**(1):196–7. DOI: 10.1002/hep.20881; PUBMED: 16374864

**Tripathi 2007**

Tripathi D, Graham C, Hayes PC. Variceal band ligation versus beta-blockers for primary prevention of variceal bleeding: a meta-analysis. *European Journal of Gastroenterology & Hepatology* 2007;**19**(10):835–45. DOI: 10.1097/MEG.0b013e3282748f07; PUBMED: 17873606

**van Buuren 2003**

van Buuren HR, Rasch MC, Batenburg PL, Bolwerk CJ, Nicolai JJ, van der Werf SD, et al. Endoscopic sclerotherapy compared with no specific treatment for the primary prevention of bleeding from esophageal varices. A randomized controlled multicentre trial [ISRCTN03215899]. *BMC Gastroenterology* 2003;**3**:22. DOI: 10.1186/1471-230X-3-22; PUBMED: 12919638

**Vlachogiannakos 2000**

Vlachogiannakos J, Goulis J, Patch D, Burroughs AK. Review article: primary prophylaxis for portal hypertensive bleeding in cirrhosis. *Alimentary Pharmacology & Therapeutics* 2000;**14**(7):851–60. [PUBMED: 10886040]

**Wetterslev 2008**

Wetterslev J, Thorlund K, Brok J, Gluud C. Trial Sequential Analysis may establish when firm evidence is reached in

cumulative meta-analysis. *Journal of Clinical Epidemiology* 2008;**61**(1):64–75. DOI: 10.1016/j.jclinepi.2007.03.013; PUBMED: 18083463

**Wong 2000**

Wong T, Pereira SP, McNair A, Harrison PM. A prospective, randomized comparison of the ease and safety of variceal ligation using a multiband vs. a conventional ligation device. *Endoscopy* 2000;**32**:931–4. DOI: 10.1055/s-2000-9617; PUBMED: 11147940

**Xie 2014**

Xie Y-D, Feng B, Gao Y, Wei L. Effect of abstinence from alcohol on survival of patients with alcoholic cirrhosis: a systematic review and meta-analysis. *Hepatology Research* 2014;**44**(4):436–49. DOI: 10.1111/hepr.12131; PUBMED: 23607793

**Yang 1998**

Yang WG, Hou MC, Lin HC, Kuo BI, Lee FY, Chang FY, et al. Effect of sucralfate granules in suspension on endoscopic variceal sclerotherapy induced ulcer: analysis of the factors determining ulcer healing. *Journal of Gastroenterology & Hepatology* 1998;**13**(2):225–31. [PUBMED: 10221828]

**References to other published versions of this review**

**Yong 2017**

Yong CW, Vadera S, Morgan MY, Gluud LL. Banding ligation versus no intervention for primary prevention in adults with oesophageal varices. *Cochrane Database of Systematic Reviews* 2017, Issue 5. DOI: 10.1002/14651858.CD012673

\* Indicates the major publication for the study

## CHARACTERISTICS OF STUDIES

### Characteristics of included studies [ordered by study ID]

#### Chen 1997

Methods	Multicentre, open, randomised clinical trial	
Participants	<p><b>Included participants:</b> cirrhosis (implied not stipulated) and oesophageal varices with no history of previous upper gastrointestinal bleeding (n = 156) (Table 1)</p> <p><b>Age:</b> not reported</p> <p><b>Proportion of men:</b> not reported</p> <p><b>Aetiology of cirrhosis:</b> not reported</p> <p><b>Child-Pugh score:</b> not reported</p> <p><b>Presence of ascites:</b> not reported</p>	
Interventions	<p><b>Intervention comparison:</b></p> <p><b>Band ligation</b> (n = 80) (Table 2)</p> <ul style="list-style-type: none"> <li>Participants who bled during follow-up were banded, if possible</li> </ul> <p><b>No intervention</b> (n = 76)</p> <ul style="list-style-type: none"> <li>Participants who bled during follow-up were banded if possible</li> </ul> <p><b>Cointerventions:</b> no information provided</p>	
Outcomes	<p><b>Outcomes included in the meta-analyses</b></p> <ul style="list-style-type: none"> <li>Mortality</li> <li>Upper gastrointestinal bleeding</li> <li>Variceal bleeding</li> <li>Serious adverse events</li> </ul>	
Inclusion period	Not provided	
Country	Taiwan	
Duration of follow-up	Median 32 months	
Notes	<p><b>Publication status:</b> abstract; further information sought from the authors but not forthcoming</p> <ul style="list-style-type: none"> <li>Participants in both groups were well matched in terms of demographic and clinical characteristics</li> </ul> <p><b>For-profit funding:</b> not described</p>	
<b>Risk of bias</b>		
<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Random sequence generation (selection bias)	Unclear risk	Not described
Allocation concealment (selection bias)	Unclear risk	Not described

Chen 1997 (Continued)

Blinding of participants and personnel (performance bias) All outcomes	High risk	Open trial without blinding
Blinding of outcome assessment (detection bias) All outcomes	High risk	Open trial without blinding
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	No information provided on the number of participants with missing outcome data (losses to follow-up or withdrawals)
Selective reporting (reporting bias)	Low risk	Clinically relevant outcomes are reported. We did not have access to the trial protocol
Other bias	Low risk	No other biases identified
Overall bias assessment (mortality)	High risk	High risk of bias
Overall bias assessment (non-mortality outcomes)	High risk	High risk of bias

Lay 1997

Methods	Single-centre, open randomised clinical trial
Participants	<p><b>Included participants:</b> cirrhosis and oesophageal varices at high risk of bleeding but no previous history of upper gastrointestinal bleeding (n = 126) (Table 1)</p> <p><b>Age</b> (mean ± standard deviation):</p> <ul style="list-style-type: none"> <li>banding 56.0 ± 11.0 years</li> <li>no intervention 55.0 ± 10.0 years</li> </ul> <p><b>Proportion of men:</b></p> <ul style="list-style-type: none"> <li>banding 80.6%</li> <li>no intervention 79.7%</li> </ul> <p><b>Aetiology of cirrhosis</b> (banding; no intervention):</p> <ul style="list-style-type: none"> <li>alcohol 19.4%; 17.2%</li> <li>chronic viral hepatitis 75.8%; 76.6%</li> </ul> <p><b>Child-Pugh score</b> (A/B/C):</p> <ul style="list-style-type: none"> <li>banding 17/22/23</li> <li>no intervention 16/23/25</li> </ul> <p><b>Presence of ascites:</b></p> <ul style="list-style-type: none"> <li>banding 33 (53%)</li> <li>no intervention 32 (50%)</li> </ul>
Interventions	<p><b>Intervention comparison:</b></p> <p><b>Band ligation</b> (n = 62) (Table 2)</p> <ul style="list-style-type: none"> <li>Participants who bled during follow-up underwent endoscopic sclerotherapy</li> </ul> <p><b>No intervention</b> (n = 64)</p>

Lay 1997 (Continued)

	<ul style="list-style-type: none"> <li>• Participants who bled during follow-up underwent endoscopic sclerotherapy</li> </ul> <p><b>Cointervention:</b> sucralfate given routinely to participants in the band ligation group</p>	
Outcomes	<p><b>Outcomes included in the meta-analyses</b></p> <ul style="list-style-type: none"> <li>• Mortality</li> <li>• Upper gastrointestinal bleeding</li> <li>• Variceal bleeding</li> <li>• Serious adverse event</li> </ul>	
Inclusion period	January 1993 to December 1995	
Country	Taiwan	
Duration of follow-up	<p>Mean ± SD (days):</p> <ul style="list-style-type: none"> <li>• banding 370 ± 120</li> <li>• no intervention 380 ± 130</li> </ul>	
Notes	<p><b>Publication status:</b> full paper</p> <ul style="list-style-type: none"> <li>• The two groups were well-matched with regard to age, sex, and the severity of their liver disease</li> </ul> <p><b>For-profit funding:</b> not described</p>	
<b>Risk of bias</b>		
<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Random sequence generation (selection bias)	Unclear risk	Not described
Allocation concealment (selection bias)	Unclear risk	Sealed-envelope method. The text does not clarify if the envelopes were serially numbered or opaque
Blinding of participants and personnel (performance bias) All outcomes	High risk	Open randomised clinical trial without blinding
Blinding of outcome assessment (detection bias) All outcomes	High risk	Open randomised clinical trial without blinding
Incomplete outcome data (attrition bias) All outcomes	Low risk	There are no missing outcome data and all participants are included in the analyses
Selective reporting (reporting bias)	Low risk	Clinically relevant outcomes are defined and reported. We did not have access to the trial protocol

Lay 1997 (Continued)

Other bias	Unclear risk	Sucralfate given routinely to participants in the band ligation group
Overall bias assessment (mortality)	High risk	High risk of bias
Overall bias assessment (non-mortality outcomes)	High risk	High risk of bias

Lo 1999

Methods	Single-centre, open randomised clinical trial
Participants	<p><b>Included participants:</b> cirrhosis and oesophageal varices at high risk of bleeding but no previous history of upper gastrointestinal bleeding (n = 133) (Table 1)</p> <p><b>Age</b> (mean ± standard deviation):</p> <ul style="list-style-type: none"> <li>banding 55.0 ± 12.0 years</li> <li>no intervention 57.0 ± 11.0 years</li> </ul> <p><b>Proportion of men:</b></p> <ul style="list-style-type: none"> <li>banding 84.4%</li> <li>no intervention 84.1%</li> </ul> <p><b>Aetiology of cirrhosis</b> (banding; no intervention):</p> <ul style="list-style-type: none"> <li>alcohol 28.1%; 31.7%</li> <li>chronic viral hepatitis 65.6%; 63.5%</li> </ul> <p><b>Child-Pugh score</b> (A/B/C):</p> <ul style="list-style-type: none"> <li>banding 16/30/18</li> <li>no intervention 20/25/18</li> </ul> <p><b>Presence of ascites:</b></p> <ul style="list-style-type: none"> <li>banding 21 (33%)</li> <li>no intervention 22 (35%)</li> </ul>
Interventions	<p><b>Intervention comparison</b> (see notes)</p> <p><b>Band ligation:</b> (n = 64) (Table 2)</p> <ul style="list-style-type: none"> <li>Participants who developed recurrent varices (n = 12) underwent further banding</li> <li>Participants who bled during follow-up were banded, if possible</li> </ul> <p><b>No intervention:</b> (n = 63)</p> <ul style="list-style-type: none"> <li>Participants who bled during follow-up were banded, if possible</li> </ul> <p><b>Cointerventions:</b> sucralfate given routinely to participants in the band ligation group</p>
Outcomes	<p><b>Outcomes included in the meta-analyses</b></p> <ul style="list-style-type: none"> <li>Mortality</li> <li>Upper gastrointestinal bleeding</li> <li>Variceal bleeding</li> <li>Serious adverse events</li> </ul>
Inclusion period	January 1992 to March 1995
Country	Taiwan

Duration of follow-up	Median - banding: 2 years and 4 months; no intervention - 2 years and 6 months	
Notes	<p><b>Publication status:</b> full-paper</p> <ul style="list-style-type: none"> <li>• The two groups were well-matched for age, sex, aetiology of cirrhosis, variceal grading and severity of liver disease</li> <li>• Overall 66 participants were randomised to banding and 67 to no intervention; 6 participants were lost to follow-up and were excluded from the analyses</li> <li>• The number of participants in the control group with non-serious adverse events was not reported. Thus, we were not able to include this randomised clinical trial in the analysis of non-serious adverse events (Table 3).</li> </ul> <p><b>For-profit funding:</b> not described</p>	
<b>Risk of bias</b>		
<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Random sequence generation (selection bias)	Low risk	Allocation sequence based on computer generated random numbers
Allocation concealment (selection bias)	Unclear risk	Not described
Blinding of participants and personnel (performance bias) All outcomes	High risk	Open randomised clinical trial without blinding
Blinding of outcome assessment (detection bias) All outcomes	High risk	Open randomised clinical trial without blinding
Incomplete outcome data (attrition bias) All outcomes	High risk	Six of the original 133 participants were lost to follow-up: banding (n = 2); no intervention (n = 4); they were not included in the analyses
Selective reporting (reporting bias)	Low risk	Clinically relevant outcomes were defined and reported. We did not have access to the trial protocol
Other bias	Unclear risk	Sucralfate given routinely to participants in the band ligation group
Overall bias assessment (mortality)	High risk	High risk of bias
Overall bias assessment (non-mortality outcomes)	High risk	High risk of bias

Methods	Single-centre, open randomised clinical trial
Participants	<p><b>Included participants:</b> cirrhosis with high-risk oesophageal varices (n = 68) or non-cirrhotic portal hypertension/extrahepatic portal vein block with high risk oesophageal varices (n = 6), with no history of upper gastrointestinal bleeding (Table 1)</p> <p><b>Age</b> (mean ± standard deviation):</p> <ul style="list-style-type: none"> <li>• banding 41.8 ± 13.7 years</li> <li>• no intervention 39.3 ± 11.9 years</li> </ul> <p><b>Proportion of men:</b></p> <ul style="list-style-type: none"> <li>• banding 80.0%</li> <li>• no intervention 78.8%</li> </ul> <p><b>Aetiology of cirrhosis</b> (banding; no intervention):</p> <ul style="list-style-type: none"> <li>• alcohol 40.0%; 33.3%</li> <li>• chronic viral hepatitis not specified</li> </ul> <p><b>Child-Pugh score</b> (A/B/C):</p> <ul style="list-style-type: none"> <li>• banding 9/16/11</li> <li>• no intervention 10/13/10</li> </ul> <p><b>Presence of ascites:</b></p> <ul style="list-style-type: none"> <li>• banding 30 (85.7%)</li> <li>• no intervention 26 (78.8%)</li> </ul>
Interventions	<p><b>Intervention comparison:</b></p> <p><b>Band ligation</b> (n = 35) (Table 2)</p> <ul style="list-style-type: none"> <li>• participants who developed recurrent varices (n = 10) underwent further banding</li> <li>• participants who bled during follow-up were banded, if possible</li> </ul> <p><b>No intervention</b> (n = 33)</p> <ul style="list-style-type: none"> <li>• participants who bled during follow-up were banded, if possible</li> </ul> <p><b>Cointerventions:</b> no information provided</p>
Outcomes	<p><b>Outcomes included in the meta-analyses:</b></p> <ul style="list-style-type: none"> <li>• Mortality</li> <li>• Upper gastrointestinal bleeding</li> <li>• Variceal bleeding</li> <li>• Serious adverse events</li> </ul>
Inclusion period	Not described
Country	India
Duration of follow-up	Mean ± SD (months): banding 13.9 ± 4.6; no intervention 14.2 ± 5.5
Notes	<p><b>Publication status:</b> full paper</p> <ul style="list-style-type: none"> <li>• The number of participants described in this paper is inconsistent</li> <li>• The participants in the two groups were well-matched in relation to their demography, the aetiology and severity of their liver disease and their clinical presentation</li> <li>• The number of participants in the control group who suffered non-serious adverse events is not reported. Thus, we were not able to include this randomised clinical trial in the analysis of non-serious adverse events (Table 3).</li> </ul>

Sarin 1996 (Continued)

For-profit funding: not described		
<i>Risk of bias</i>		
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Not reported
Allocation concealment (selection bias)	Unclear risk	Not reported
Blinding of participants and personnel (performance bias) All outcomes	High risk	Open randomised clinical trial without blinding
Blinding of outcome assessment (detection bias) All outcomes	High risk	Open randomised clinical trial without blinding
Incomplete outcome data (attrition bias) All outcomes	Low risk	There are no missing outcomes and all participants are included in the analyses
Selective reporting (reporting bias)	Low risk	Clinically relevant outcomes are defined and reported. We did not have access to the trial protocol
Other bias	Low risk	No other biases identified
Overall bias assessment (mortality)	High risk	High risk of bias
Overall bias assessment (non-mortality outcomes)	High risk	High risk of bias

Svoboda 1999

Methods	Single-centre, open randomised clinical trial
Participants	<p><b>Included participants:</b> cirrhosis and 'advanced' oesophageal varices with no history of upper gastrointestinal bleeding (n = 102) (Table 1)</p> <p><b>Age</b> (mean ± standard deviation):</p> <ul style="list-style-type: none"> <li>banding 48.0 ± 12.0 years</li> <li>no intervention 47.0 ± 11.0 years</li> </ul> <p><b>Proportion of men:</b></p> <ul style="list-style-type: none"> <li>banding 73.1%</li> <li>no intervention 80.0%</li> </ul> <p><b>Aetiology of cirrhosis</b> (banding; no intervention):</p> <ul style="list-style-type: none"> <li>alcohol 67.3%; 68.0%</li> <li>chronic viral hepatitis 32.7%; 32.0%</li> </ul>

	<b>Child-Pugh score (A/B/C):</b> <ul style="list-style-type: none"> <li>banding 32/14/6</li> <li>no intervention 28/16/6</li> </ul> <b>Presence of ascites:</b> not reported	
Interventions	<b>Intervention comparison:</b> <b>Band ligation</b> (n = 52) (Table 2) <ul style="list-style-type: none"> <li>participants who developed recurrent varices (31%) underwent further banding</li> <li>participants who bled during follow-up underwent endoscopic sclerotherapy and somatostatin</li> </ul> <b>No intervention</b> (n = 50) <ul style="list-style-type: none"> <li>participants who bled during follow-up underwent endoscopic sclerotherapy and somatostatin</li> </ul> <b>Cointervention:</b> the angiotensin-converting enzyme (ACE) inhibitor enalapril (later quinapril) (2 × 5 mg/d to 10 mg/d) was administered orally to participants in both groups to reduce portal pressure	
Outcomes	<b>Outcomes included in meta-analyses</b> <ul style="list-style-type: none"> <li>Mortality</li> <li>Upper gastrointestinal bleeding</li> <li>Variceal bleeding</li> <li>Serious adverse events</li> </ul>	
Inclusion period	September 1994 to September 1997	
Country	Czech Republic	
Duration of follow-up	Mean ± SD (months): banding 25 ± 11; no intervention 26 ± 10	
Notes	<b>Publication status:</b> full paper <ul style="list-style-type: none"> <li>This trial also included a second intervention arm in which participants underwent endoscopic sclerotherapy (n = 55)</li> <li>Participants in the two groups were well-matched on basic clinical characteristics</li> </ul> <b>For-profit funding:</b> none	
<b>Risk of bias</b>		
<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Random sequence generation (selection bias)	Unclear risk	Not described
Allocation concealment (selection bias)	Unclear risk	Not described
Blinding of participants and personnel (performance bias) All outcomes	High risk	Open randomised clinical trial without blinding

**Svoboda 1999** (Continued)

Blinding of outcome assessment (detection bias) All outcomes	High risk	Open randomised clinical trial without blinding
Incomplete outcome data (attrition bias) All outcomes	High risk	A total of 186 participants were randomised: 29 were lost to follow-up; the remaining 157 were all evaluated, including 55 randomised to sclerotherapy (not included in our analyses); 52 randomised to band ligation and 50 randomised to no intervention. The number of participants lost from each group is not specified and so adjustments could not be made
Selective reporting (reporting bias)	Low risk	Clinically relevant outcomes are defined and reported; we did not have access to the trial protocol
Other bias	Low risk	No other biases identified
Overall bias assessment (mortality)	High risk	High risk of bias
Overall bias assessment (non-mortality outcomes)	High risk	High risk of bias

**Triantos 2005**

Methods	Three centre, open, randomised clinical trial
Participants	<p><b>Included participants:</b> cirrhosis and small (n = 31) or large (n = 21) oesophageal varices with no previous portal hypertension-associated bleeding in whom beta-blockers were contraindicated or were not tolerated (n = 52) (Table 1)</p> <p><b>Age</b> (mean ± standard deviation):</p> <ul style="list-style-type: none"> <li>• banding 60 ± 9.37 years</li> <li>• no intervention 63.0 ± 10.27 years</li> </ul> <p><b>Proportion of men:</b></p> <ul style="list-style-type: none"> <li>• banding 84.0%</li> <li>• no intervention 63.0%</li> </ul> <p><b>Aetiology of cirrhosis</b> (banding; no intervention):</p> <ul style="list-style-type: none"> <li>• alcohol 36.0%; 33.3%</li> <li>• chronic viral hepatitis 44.0%; 25.9%</li> </ul> <p><b>Child-Pugh score</b> (A/B/C):</p> <ul style="list-style-type: none"> <li>• banding 9/6/10</li> <li>• no intervention 8/7/12</li> </ul> <p><b>Presence of ascites:</b></p> <ul style="list-style-type: none"> <li>• banding 11 (44.0%)</li> <li>• no intervention 19 (70.4%)</li> </ul>

Interventions	<b>Intervention comparison:</b> <b>Band ligation</b> (n = 25) (Table 2) <ul style="list-style-type: none"> <li>• participants who developed recurrent varices (7/20) underwent further banding</li> <li>• participants who bled during follow-up underwent endoscopic sclerotherapy and somatostatin</li> </ul> <b>No intervention</b> (n = 27) <ul style="list-style-type: none"> <li>• participants who bled during follow-up underwent band ligation</li> </ul>	
Outcomes	<b>Outcomes included in meta-analyses:</b> <ul style="list-style-type: none"> <li>• Mortality</li> <li>• Upper gastrointestinal bleeding</li> <li>• Variceal bleeding</li> <li>• Serious adverse events</li> </ul>	
Inclusion period	December 1999 to November 2003; stopped prematurely (see notes)	
Country	Greece	
Duration of follow-up	Mean follow-up (months) banding 18.3 ± 11.8; no intervention 20.6 ± 14.6	
Notes	<b>Publication status:</b> full paper <ul style="list-style-type: none"> <li>• The required sample size was 214 with 37 observed events</li> <li>• The trial was stopped in November 2003 after the inclusion of 52 participants because the number of bleeding events in the band ligation group was double that expected</li> <li>• The number of participants in the control group with non-serious adverse events was not provided. Thus, we were not able to include this randomised clinical trial in the analysis of non-serious adverse events (Table 3).</li> </ul> <b>For-profit funding:</b> none	
<b>Risk of bias</b>		
<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Random sequence generation (selection bias)	Low risk	Use of random number table using a blocked code
Allocation concealment (selection bias)	Low risk	Use of sealed opaque envelopes, opened in a numbered sequence
Blinding of participants and personnel (performance bias) All outcomes	High risk	Open randomised clinical trial without blinding
Blinding of outcome assessment (detection bias) All outcomes	High risk	Open randomised clinical trial without blinding

Incomplete outcome data (attrition bias) All outcomes	Low risk	Two of the 25 participants in the intervention group refused treatment; while a further two were lost to follow-up. Two of the 27 participants in the intervention groups were lost to follow-up The authors included all 52 participants in their analyses.
Selective reporting (reporting bias)	Low risk	Clinically relevant outcomes are defined and reported. We did not have access to the trial protocol
Other bias	Low risk	No other biases identified
Overall bias assessment (mortality)	Low risk	Low risk of bias
Overall bias assessment (non-mortality outcomes)	High risk	High risk of bias

### Characteristics of excluded studies [ordered by study ID]

Study	Reason for exclusion
<a href="#">Gameel 2005</a>	Randomised clinical trial evaluating band ligation (n = 16), sclerotherapy (n = 17), or no intervention (n = 17) for primary prevention of variceal bleeding in participants with portal hypertension secondary to schistosomiasis and 'high risk' varices; 84% of the participants also had chronic viral hepatitis and cirrhosis. One participant in the band ligation group died compared with none in the no intervention group while no bleeding episodes occurred in the band ligation group in the first six months compared to three bleeding episodes in the no intervention group This trial, which is published in abstract form only, was excluded because the portal hypertension was secondary to schistosomal portal hypertension
<a href="#">Lim 2009</a>	Retrospective observational study undertaken in 258 adults with cirrhosis awaiting liver transplantation who underwent upper gastrointestinal endoscopy. Of these, 101 had varices deemed to be at high risk of bleeding and underwent banding until variceal eradication was achieved or they were transplanted. Failed prophylaxis occurred in 2 participants (2%), and there were 3 episodes (1.2%) of acute haematemesis from band-induced ulceration. One patient (1%) had mild oesophageal stricturing postbanding without dysphagia. None died This study was excluded as it was observational with no control group
<a href="#">Omar 2000</a>	Randomised clinical trial evaluating band ligation (n = 36) versus no intervention (n = 38) for primary prophylaxis of variceal bleeding in participants with non-alcoholic cirrhosis and/or schistosomal hepatic fibrosis and large oesophageal varices. No deaths were reported. Variceal bleeding occurred in one participant in the banding group compared to four in the no intervention group (P > 0.05) This trial, which was published in abstract form only, was excluded as no separate analyses were provided of the participants with and without cirrhosis

## DATA AND ANALYSES

### Comparison 1. Band ligation versus no intervention

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Mortality, by liver injury	6	637	Risk Ratio (M-H, Random, 95% CI)	0.55 [0.43, 0.70]
1.1 RCTs including participants with cirrhosis	5	569	Risk Ratio (M-H, Random, 95% CI)	0.55 [0.43, 0.71]
1.2 RCTs including participants with or without cirrhosis	1	68	Risk Ratio (M-H, Random, 95% CI)	0.47 [0.16, 1.42]
2 Mortality, by size of varices	6	637	Risk Ratio (M-H, Random, 95% CI)	0.55 [0.43, 0.70]
2.1 RCTs including participants with medium and large varices	5	585	Risk Ratio (M-H, Random, 95% CI)	0.54 [0.42, 0.69]
2.2 RCTs including participants with small or large varices	1	52	Risk Ratio (M-H, Random, 95% CI)	0.69 [0.32, 1.49]
3 Upper gastrointestinal bleeding, by liver injury	6	637	Risk Ratio (M-H, Random, 95% CI)	0.44 [0.28, 0.72]
3.1 RCTs including participants with cirrhosis	5	569	Risk Ratio (M-H, Random, 95% CI)	0.48 [0.29, 0.80]
3.2 RCTs including participants with or without cirrhosis	1	68	Risk Ratio (M-H, Random, 95% CI)	0.22 [0.07, 0.70]
4 Upper gastrointestinal bleeding, by size of varices	6	637	Risk Ratio (M-H, Random, 95% CI)	0.44 [0.28, 0.72]
4.1 RCTs including participants with medium and large varices	5	585	Risk Ratio (M-H, Random, 95% CI)	0.40 [0.27, 0.59]
4.2 RCTs including participants with small or large varices	1	52	Risk Ratio (M-H, Random, 95% CI)	2.7 [0.57, 12.68]
5 Serious adverse events, by liver injury	6	637	Risk Ratio (M-H, Random, 95% CI)	0.55 [0.43, 0.70]
5.1 RCTs including participants with cirrhosis	5	569	Risk Ratio (M-H, Random, 95% CI)	0.57 [0.44, 0.73]
5.2 RCTs including participants with or without cirrhosis	1	68	Risk Ratio (M-H, Random, 95% CI)	0.35 [0.16, 0.79]
6 Serious adverse events, by size of varices	6	637	Risk Ratio (M-H, Random, 95% CI)	0.55 [0.43, 0.70]
6.1 RCTs including participants with medium and large varices	5	585	Risk Ratio (M-H, Random, 95% CI)	0.53 [0.41, 0.69]

6.2 RCTs including participants with small or large varices	1	52	Risk Ratio (M-H, Random, 95% CI)	0.75 [0.39, 1.44]
<b>7 Variceal bleeding, by liver injury</b>	6	637	Risk Ratio (M-H, Random, 95% CI)	0.43 [0.27, 0.69]
7.1 RCTs including participants with cirrhosis	5	569	Risk Ratio (M-H, Random, 95% CI)	0.47 [0.28, 0.78]
7.2 RCTs including participants with or without cirrhosis	1	68	Risk Ratio (M-H, Random, 95% CI)	0.22 [0.07, 0.70]
<b>8 Variceal bleeding, by size of varices</b>	6	637	Risk Ratio (M-H, Random, 95% CI)	0.43 [0.27, 0.69]
8.1 RCTs including participants with medium and large varices	5	585	Risk Ratio (M-H, Random, 95% CI)	0.38 [0.26, 0.55]
8.2 RCTs including participants with small or large varices	1	52	Risk Ratio (M-H, Random, 95% CI)	2.7 [0.57, 12.68]

## Comparison 2. Band ligation versus no intervention: worst-case, extreme worst-case, and extreme best-case scenario analyses

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
<b>1 Mortality</b>	6		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
1.1 Worst-case scenario analysis	6	637	Risk Ratio (M-H, Random, 95% CI)	0.59 [0.46, 0.74]
1.2 Extreme worst-case scenario analysis	6	637	Risk Ratio (M-H, Random, 95% CI)	0.59 [0.46, 0.74]
1.3 Extreme best-case scenario analysis	6	637	Risk Ratio (M-H, Random, 95% CI)	0.53 [0.42, 0.68]
<b>2 Upper gastrointestinal bleeding</b>	6		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
2.1 Worst-case scenario analysis	6	637	Risk Ratio (M-H, Random, 95% CI)	0.48 [0.28, 0.83]
2.2 Extreme worst-case scenario analysis	6	637	Risk Ratio (M-H, Random, 95% CI)	0.48 [0.28, 0.83]
2.3 Extreme best-case scenario analysis	6	637	Risk Ratio (M-H, Random, 95% CI)	0.43 [0.27, 0.67]
<b>3 Serious adverse events</b>	6		Risk Ratio (M-H, Fixed, 95% CI)	Subtotals only
3.1 Worst-case scenario analysis	6	637	Risk Ratio (M-H, Fixed, 95% CI)	0.56 [0.47, 0.66]
3.2 Extreme worst-case scenario analysis	6	637	Risk Ratio (M-H, Fixed, 95% CI)	0.56 [0.47, 0.66]
3.3 Extreme best-case scenario analysis	6	637	Risk Ratio (M-H, Fixed, 95% CI)	0.54 [0.45, 0.64]
<b>4 Variceal bleeding</b>	6		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
4.1 Worst-case scenario analysis	6	637	Risk Ratio (M-H, Random, 95% CI)	0.47 [0.27, 0.82]


4.2 Extreme worst-case scenario analysis	6	637	Risk Ratio (M-H, Random, 95% CI)	0.47 [0.27, 0.82]
4.3 Extreme best-case scenario analysis	6	637	Risk Ratio (M-H, Random, 95% CI)	0.41 [0.26, 0.65]

### Analysis 1.1. Comparison 1 Band ligation versus no intervention, Outcome 1 Mortality, by liver injury.

Review: Band ligation versus no intervention for primary prevention of upper gastrointestinal bleeding in adults with cirrhosis and oesophageal varices

Comparison: 1 Band ligation versus no intervention

Outcome: 1 Mortality, by liver injury




## Analysis 1.2. Comparison 1 Band ligation versus no intervention, Outcome 2 Mortality, by size of varices.

Review: Band ligation versus no intervention for primary prevention of upper gastrointestinal bleeding in adults with cirrhosis and oesophageal varices

Comparison: 1 Band ligation versus no intervention

Outcome: 2 Mortality, by size of varices




### Analysis 1.3. Comparison 1 Band ligation versus no intervention, Outcome 3 Upper gastrointestinal bleeding, by liver injury.

Review: Band ligation versus no intervention for primary prevention of upper gastrointestinal bleeding in adults with cirrhosis and oesophageal varices

Comparison: 1 Band ligation versus no intervention

Outcome: 3 Upper gastrointestinal bleeding, by liver injury




### Analysis 1.4. Comparison 1 Band ligation versus no intervention, Outcome 4 Upper gastrointestinal bleeding, by size of varices.

Review: Band ligation versus no intervention for primary prevention of upper gastrointestinal bleeding in adults with cirrhosis and oesophageal varices

Comparison: 1 Band ligation versus no intervention

Outcome: 4 Upper gastrointestinal bleeding, by size of varices




**Analysis 1.5. Comparison 1 Band ligation versus no intervention, Outcome 5 Serious adverse events, by liver injury.**

Review: Band ligation versus no intervention for primary prevention of upper gastrointestinal bleeding in adults with cirrhosis and oesophageal varices

Comparison: 1 Band ligation versus no intervention

Outcome: 5 Serious adverse events, by liver injury




**Analysis 1.6. Comparison 1 Band ligation versus no intervention, Outcome 6 Serious adverse events, by size of varices.**

Review: Band ligation versus no intervention for primary prevention of upper gastrointestinal bleeding in adults with cirrhosis and oesophageal varices

Comparison: 1 Band ligation versus no intervention

Outcome: 6 Serious adverse events, by size of varices




### Analysis 1.7. Comparison 1 Band ligation versus no intervention, Outcome 7 Variceal bleeding, by liver injury.

Review: Band ligation versus no intervention for primary prevention of upper gastrointestinal bleeding in adults with cirrhosis and oesophageal varices

Comparison: 1 Band ligation versus no intervention

Outcome: 7 Variceal bleeding, by liver injury




### Analysis 1.8. Comparison 1 Band ligation versus no intervention, Outcome 8 Variceal bleeding, by size of varices.

Review: Band ligation versus no intervention for primary prevention of upper gastrointestinal bleeding in adults with cirrhosis and oesophageal varices

Comparison: 1 Band ligation versus no intervention

Outcome: 8 Variceal bleeding, by size of varices




## Analysis 2.1. Comparison 2 Band ligation versus no intervention: worst-case, extreme worst-case, and extreme best-case scenario analyses, Outcome 1 Mortality.


Review: Band ligation versus no intervention for primary prevention of upper gastrointestinal bleeding in adults with cirrhosis and oesophageal varices

Comparison: 2 Band ligation versus no intervention: worst-case, extreme worst-case, and extreme best-case scenario analyses

Outcome: 1 Mortality



(Continued ...)




### Analysis 2.2. Comparison 2 Band ligation versus no intervention: worst-case, extreme worst-case, and extreme best-case scenario analyses, Outcome 2 Upper gastrointestinal bleeding.


Review: Band ligation versus no intervention for primary prevention of upper gastrointestinal bleeding in adults with cirrhosis and oesophageal varices

Comparison: 2 Band ligation versus no intervention: worst-case, extreme worst-case, and extreme best-case scenario analyses

Outcome: 2 Upper gastrointestinal bleeding



(Continued . . .)




### Analysis 2.3. Comparison 2 Band ligation versus no intervention: worst-case, extreme worst-case, and extreme best-case scenario analyses, Outcome 3 Serious adverse events.


Review: Band ligation versus no intervention for primary prevention of upper gastrointestinal bleeding in adults with cirrhosis and oesophageal varices

Comparison: 2 Band ligation versus no intervention: worst-case, extreme worst-case, and extreme best-case scenario analyses

Outcome: 3 Serious adverse events



(Continued ...)




**Analysis 2.4. Comparison 2 Band ligation versus no intervention: worst-case, extreme worst-case, and extreme best-case scenario analyses, Outcome 4 Variceal bleeding.**


Review: Band ligation versus no intervention for primary prevention of upper gastrointestinal bleeding in adults with cirrhosis and oesophageal varices

Comparison: 2 Band ligation versus no intervention: worst-case, extreme worst-case, and extreme best-case scenario analyses

Outcome: 4 Variceal bleeding



(Continued . . .)



## ADDITIONAL TABLES

Table 1. Details of the endoscopic findings and trial randomisation by variceal characteristics

Trial	Inclusion criteria	Assessment of varices	Randomisation by variceal characteristics	Gastric varices or portal hypertensive gastropathy
Chen 1997	Not reported	Not stipulated	Not reported	Not reported
Lay 1997	Participants were assessed for risk of bleeding (Beppu 1981), using criteria defined by the Japanese Re-	Not stipulated	Not described	Participants with gastric or ectopic varices at recruitment were excluded During follow-up, 4 (6%)

**Table 1. Details of the endoscopic findings and trial randomisation by variceal characteristics** (Continued)

	search Society for Portal Hypertension (Inokuchi 1980). The included participants had blue varices of at least F2 or F3 size with at least one of the following: cherry-red spots (++, +++), red wale markings (++, +++), haematocystic spots (+)			participants in the banding group and 3 (5%) in the control group developed gastric varices
Lo 1999	F2 or F3, associated with a moderate degree of red colour signs (red wale markings, cherry-red spots or haematocystic spots (Beppu 1981))	Not stipulated	<p><b>F2</b> Banding: 27/64 (42%) No intervention: 30/63 (48%)</p> <p><b>F3</b> Banding: 37/64 (58%) No intervention: 33/63 (52%)</p> <p><b>Red colour signs moderate</b> Banding: 33/64 (52%) No intervention: 36/63 (57%)</p> <p><b>Red colour signs severe</b> Banding: 31/64 (48%) No intervention: 27/63 (43%)</p>	Participants with gastric varices at recruitment were excluded During follow-up, 8 (12%) participants in the banding group and 3 (5%) in the no intervention group developed gastric varices During follow-up, 1 (1.6%) patient in the banding group and 2 (3.2%) in the no intervention group developed gastropathy
Sarin 1996	Participants with large varices > 5 mm were assessed for risk of bleeding (Beppu 1981), using criteria defined by the Japanese Research Society for Portal Hypertension (Inokuchi 1980). The included participants had blue varices of at least F2 or F3 size with one or more red colour signs; (cherry-red spots, red wale markings or haematocystic spots)	Variceal size and grade assessed by two independent observers	Not reported	The presence/absence of gastric varices was recorded at initial assessment; no further mention and so absence is assumed Portal hypertensive gastropathy present in 3 (8.6%) participants at inclusion and developed in a further two postbanding
Svoboda 1999	Grade III or IV, or grade II with signs of high risk, classified using the Paquet's system (Paquet 1978)	Not stipulated	<p><b>Grade II</b> Banding: 2/52 (4%) Control: 1/50 (2%)</p> <p><b>Grade III</b> Banding: 36/52 (69%)</p>	Not described

**Table 1. Details of the endoscopic findings and trial randomisation by variceal characteristics** (Continued)

			No intervention: 38/50 (76%) <b>Grade IV</b> Banding: 14/52 (27%) No intervention: 11/50 (22%)	
<a href="#">Triantos 2005</a>	Varices of any size: Small varices: < 5 mm diameter Large varices: diameter of largest varix > 5 mm Measured with open forceps and not disappearing on oesophageal insufflation	Assessed endoscopically by two independent observers	<b>Small varices</b> Banding: 14/25 (56%) No intervention: 17/27 (63%) <b>Large varices</b> Banding: 11/25 (44%) No intervention: 10/27 (37%) <b>Red spots</b> Banding: 9/25 (36%) No intervention: 8/27 (30%)	Gastric varices present at inclusion Banding: 2/25 (8%) No intervention: 1/27 (4%) No further participants in the banding group developed gastric varices during follow-up; two participants in whom the varices were obliterated appear to have developed portal hypertensive gastropathy from which they bled

Japanese Research Society for Portal Hypertension classification ([Inokuchi 1980](#)) (Form: F1- straight varices; F2- enlarged tortuous varices; F3- largest sized varices; fundamental colour: Cw - white varices; Cb - blue varices; red colour signs: RC(-) - red colour signs negative; RC(+) - red colour signs positive; red wale marks: RWM - (+), (++) , (+++); cherry-red spots: CRS - (+), (++) , (+++); haematocystic spot: HCS; diffuse redness: DR; Group A: both red wale markings and cherry-red spots were negative or mild (+); Group B: both red wale markings and cherry-red spots were moderate (++) or severe (+++). Location: li - locus inferior; Lm - locus medialis; Ls - locus superior

Paquet classification: 0 - no varices; I - varices that disappear with insufflation; II - larger, usually straight, visible varices that disappear with insufflation; III - more prominent coil-shaped varices, occupying part of the lumen; IV - tortuous varices occupying the lumen ([Paquet 1978](#)).

**Table 2. Details of the procedure for band ligation, endpoints, and outcomes**

Banding	<a href="#">Chen 1997</a>	<a href="#">Lay 1997</a>	<a href="#">Lo 1999</a>	<a href="#">Sarin 1996</a>	<a href="#">Svoboda 1999</a>	<a href="#">Triantos 2005</a>
<b>Equipment</b>	Not described	Endoscopic ligating device (Bard Interventional Products, Billerica, MA, USA) with a 25 cm overtube (Olympus XQ 20, Tokyo, Japan)	Endoscopic ligating device (Bard Interventional Products, Billerica, MA, USA) with a 25 cm overtube (Olympus XQ 20, Tokyo, Japan)	Endoscopic ligating device and a 25 cm overtube (Bard Interventional Products, Tewksbury MA, USA)	Endoscopic ligation device (Suction oesophageal varices ligator, Pauldrach Medical, Garbsen, Germany) and an overtube. Later, the multiple band	Multiband Ligator 6 shooter (Wilson-Cook, Limerick, Ireland)

**Table 2. Details of the procedure for band ligation, endpoints, and outcomes** (Continued)

					ligators (Wilson-Cook Medical Inc, Winston-Salem, NC, USA, or Microvasive, Boston Scientific Corporation, Watertown, MA, USA)	
<b>Operator experience</b>	Not described	Ligation was performed by two experienced endoscopists who had performed more than 10 sessions of the procedure before the trial	Ligation was performed by two experienced endoscopists who had performed more than 10 sessions of this procedure before the trial	Not described	Ligation was performed by two experienced endoscopists; each of whom had performed $\geq 300$ endoscopic procedures (band ligation or sclerotherapy) and also to have assisted 300 times before the trial	Ligation was performed by four experienced endoscopists each of whom had performed 100 ligation sessions before the trial
<b>Technique</b>	-Variceal ligation performed at 2- to 3- week intervals	- Ligation was performed at 1 cm to 5 cm above the gastroesophageal junction; each varix was ligated with 1 to 3 rubber bands to a maximum of 10 bands/session - Procedure repeated weekly for the first 3 weeks, if possible and then every 2 weeks - Follow-up endoscopy repeated every 3 months after eradication	- Ligation was performed at 1 cm to 5 cm above the gastroesophageal junction; each varix was ligated with 1 to 2 rubber bands - Procedure repeated at intervals of 3 weeks - Follow-up endoscopy repeated every 3 months after eradication	- Varices ligated 1 cm to 2 cm above the gastroesophageal junction; 1 to 2 bands applied to each variceal column between the lower 4 cm to 5 cm of the oesophagus; every variceal column was ligated at each session - Procedure repeated at 7- to 10-day intervals - Follow-up endoscopy repeated every 3 months af	- The largest number possible (up to 6) elastic bands were positioned in the distal oesophagus at each session - The first three therapeutic sessions were performed at 2-week intervals then monthly - Follow-up endoscopy repeated every 3 months after eradication - Participants in the no treatment	- Bands were placed starting at the gastroesophageal junction and then proximally in a helical fashion for approximately 5 cm, putting at least one band on each varix - Subsequent sessions scheduled at 14-day intervals - Participants in the no intervention group were endoscoped

Table 2. Details of the procedure for band ligation, endpoints, and outcomes (Continued)

				ter eradication	group were endoscoped every 3 months	yearly
<b>Endpoint</b>	Variceal eradication	Variceal eradication	Varices obliterated or too small to be ligated	Variceal obliteration or decreasing the size to grade 1 (not possible to suck in varix for band ligation)	Varices too small to treat	Eradication or varices too small to ligate (no effect of suction)
<b>Achievement of endpoint</b>	71/80 (88.7%)	62/62 (100%)	55/64 (86%)	Banding successful in all participants, except for those who died before complete eradication (numbers not specified)	42/52 (81%) (includes 8 eradicated, 34 too small to band)	20/25 (80%)
<b>Reasons for failure</b>	Not reported	Not applicable	Reluctance (3) Asthenia (2) Aspiration pneumonia (1) Encephalopathy (1) Hepatic failure (2)	Death due to hepatic coma or bleeding (numbers not specified)	Not reported	Bleeding (3) Refusal (2)
<b>Mean (<math>\pm</math> 1 SD) number of sessions to achieve obliteration</b>	2.9 $\pm$ 0.7	3.6 $\pm$ 1.7 Mean examinations 5.1 $\pm$ 2.8	2.9 $\pm$ 0.5 (range 2 to 5)	3.2 $\pm$ 1.2	4.8 $\pm$ 1.8	Median 2 (1 to 4) Small varices, median 1 (1 to 4) Large varices, median 2 (1 to 3)
<b>Mean (<math>\pm</math> 1 SD) time to achieve obliteration</b>	Not reported	75.6 $\pm$ 28.4 days	40 $\pm$ 4 days	4.9 $\pm$ 2.2 weeks	Not reported	Median 28 (14 to 101) days
<b>Number of bands each session</b>	Not reported	Maximum did not exceed 10 bands per treatment session	1 to 2 per varix (mean not specified)	Each variceal column ligated with one to two bands (mean not specified)	Up to 6	Median: 4 (2 to 7) per session
<b>Recurrent varices</b>	Not reported	26/62 (42%) (of which 4 had a second recur-	12 (21.8%)	10 (28.6%)	16 (31.0%)	7 (35%) 3/11 with small varices and 4/8

**Table 2. Details of the procedure for band ligation, endpoints, and outcomes** (Continued)

	rence)				with large
<p>Japanese Research Society for Portal Hypertension classification (Inokuchi 1980) (Form: F1- straight varices; F2- enlarged tortuous varices; F3- largest sized varices; fundamental colour: Cw - white varices; Cb - blue varices: red colour signs: RC(-) - red colour signs negative; RC(+) - red colour signs positive; red wale marks: RWM - (+), (++) , (+++); cherry-red spots: CRS - (+), (++) , (+++); haematocystic spot: HCS: diffuse redness: DR; Group A: both red wale markings and cherry-red spots were negative or mild (+); Group B: both red wale markings and cherry-red spots were moderate (++) or severe (+++). Location: li - locus inferior; Lm - locus medialis; Ls - locus superior</p> <p>Paquet classification: 0 - no varices; I - varices that disappear with insufflation; II - larger, usually straight, visible varices that disappear with insufflation; III - more prominent coil-shaped varices, occupying part of the lumen; IV - tortuous varices occupying the lumen (Paquet 1978).</p>					

**Table 3. Non-serious adverse events associated with band ligation or no intervention**

Trial	Participants allocated to band ligation (n)	Participants allocated to no intervention (n)	Non-serious adverse event in participants allocated to band ligation
Chen 1997	80	76	Not reported
Lay 1997	62	64	Not reported
Lo 1999	66*	67*	<b>Banding:</b> oesophageal ulceration without bleeding (n = 16 (24%)), transient dysphagia (n = 7 (11%)), retrosternal pain (n = 5 (8%)), pleural effusion (n = 2 (3%)), fever > 38 °C (n = 2 (3%)) <b>No intervention:</b> not reported
Sarin 1996	35	33	<b>Banding:</b> oesophageal ulceration without bleeding (n = 24 (69%)), throat pain (n = 12 (34%)); retrosternal pain (n = 8 (23%)), dysphagia (n = 6 (17%)), fever (n = 4 (11%)) <b>No intervention:</b> not reported
Svoboda 1999	52	50	<b>Banding:</b> ulcer (n = 2 (4%)), dysphagia (n = 3 (6%)), odynophagia (n = 1 (2%)), others (n = 4 (8%)) <b>No intervention:</b> ulcer (n = 0), dysphagia (n = 4 (8%)), odynophagia (n = 2 (4%)), others (n = 1 (2%))
Triantos 2005	25**	27	<b>Banding:</b> small varices: ulcers (n = 7 (30.5%)),

**Table 3. Non-serious adverse events associated with band ligation or no intervention** (Continued)

			dysphagia (n = 5 (21.7%)), heartburn (n = 9 (39.2%)), chest pain (n = 3 (13.0%)) <i>large varices</i> : ulcers (n = 2 (8.7%)), dysphagia (n = 5 (21.7%)), heartburn (n = 4 (17.4%)), chest pain (n = 2 (8.7%)), fever (n = 1 (8.7%)) <b>No intervention</b> : not reported
--	--	--	--

\* Three participants in the banding and three participants in the no intervention groups were lost to follow-up. The authors omitted these 6 participants providing data on only 63 in the banding and 64 in the no intervention groups in their main analyses; we have included the number randomised in our analyses and recalculated the percentages of people with non-serious adverse effects using the full data set.

\*\* Two participants allocated to band ligation refused the procedure; the authors provide data on the complications which arose in the 23 participants who did undergo the procedure.

## APPENDICES

### Appendix I. Search strategies

Database	Time span	Search terms
The Cochrane Hepato-Biliary Group Controlled Trials Register	February 2019	(ligation* or banding*) AND (oesophageal or esophageal) and varic*)
Cochrane Central Register of Controlled Trials (CENTRAL) in the Cochrane Library	2019, Issue 2	#1 MeSH descriptor: [Ligation] explode all trees #2 ligation* or banding* #3 #1 or #2 #4 MeSH descriptor: [Esophageal and Gastric Varices] explode all trees #5 ((oesophageal or esophageal) and varic*) #6 #4 or #5 #7 #3 and #6
MEDLINE Ovid	1946 to February 2019	1. exp Ligation/ 2. (ligation* or banding*).mp. [mp=title, abstract, original title,

(Continued)

		<p>name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms]</p> <p>3. 1 or 2</p> <p>4. exp “Esophageal and Gastric Varices”/</p> <p>5. ((oesophageal or esophageal) and varic*).mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms]</p> <p>6. 4 or 5</p> <p>7. 3 and 6</p> <p>8. (random* or blind* or placebo* or meta-analys*).mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms]</p> <p>9. 7 and 8</p>	
Embase Ovid	1974 to February 2019	<p>1. exp ligation/</p> <p>2. (ligation* or banding*).mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword, floating subheading word]</p> <p>3. 1 or 2</p> <p>4. exp esophagus varices/</p> <p>5. ((oesophageal or esophageal) and varic*).mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword, floating subheading word]</p> <p>6. 4 or 5</p> <p>7. 3 and 6</p> <p>8. (random* or blind* or placebo* or meta-analys*).mp. [mp=title, ab-</p>	

(Continued)

		stract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword, floating sub-heading word] 9. 7 and 8	
LILACS (Bireme)	1982 to February 2019	(ligation\$ or banding\$) [Words] and ((oesophageal or esophageal) and varic\$) [Words]	
Science Citation Index EXPANDED (Web of Science)	1900 to February 2019	#5 #4 AND #3 #4 TS=(random* or blind* or placebo* or meta-analys*) #3 #2 AND #1 #2 TS=((oesophageal or esophageal) and varic*) #1 TS=(ligation* or banding*)	
Conference Proceedings Citation Index - Science (Web of Science)	1990 to February 2019	#5 #4 AND #3 #4 TS=(random* or blind* or placebo* or meta-analys*) #3 #2 AND #1 #2 TS=((oesophageal or esophageal) and varic*) #1 TS=(ligation* or banding*)	

## CONTRIBUTIONS OF AUTHORS

SV, CWKY and MYM: extracted data

LLG: cross-checked the extracted data

SV, CWKY and LLG: undertook the statistical analyses

SV and CWKY: drafted the review

LLG and MYM: critically reviewed the initial drafts

All the review authors participated in the literature searches; the selection of the randomised clinical trials to include; interpretation of the results; data analyses and approved the final version of the review, before submission.

MYM is guarantor of the review.

## DECLARATIONS OF INTEREST

SV: no conflicts of interest

CWKY: no conflicts of interest

LLG: no conflicts of interest

MYM: no conflicts of interest

## SOURCES OF SUPPORT

### Internal sources

- None, Other.

### External sources

- None, Other.

## DIFFERENCES BETWEEN PROTOCOL AND REVIEW

We changed the title to more precisely reflect the modes of action of the interventions included in the review and to make it clear that we only included adult participants. We also updated the methods according to the current recommendations of the Cochrane Hepato-Biliary Group. The updates include changes to the wording of the bias assessment, removal for-profit bias as a bias domain, obligatory inclusion of observational studies for the assessment of adverse events provided they included control data; and searching of the LILACS database. In the protocol, we stipulated that we would exclude studies which involved participants with non-cirrhotic portal hypertension, that is portal hypertension associated with schistosomiasis, portal/splenic vein thrombosis, Budd-Chiari syndrome and other rarer conditions of pre- or postsinusoidal block. No trials in which all or the majority of participants fulfilled these criteria were included. However, one large trial of patients with portal hypertension associated with cirrhosis also involved a very small number of participants with non-cirrhotic portal hypertension/portal vein block, amounting to < 10% of the total; this was included based on the premise that these few participants were not likely to significantly affect outcomes. We undertook a post hoc subgroup analyses of trials involving participants with portal hypertension secondary to cirrhosis compared to this one trial, and found no essential differences in our primary outcomes. For the Trial Sequential Analyses, we changed the setting of alpha from 3.3% to 2.5% because there were three primary outcomes. We included upper gastrointestinal bleeding as a primary not a secondary outcome because it is the most important serious adverse event encountered, and was included as one of the primary outcomes in all of the included trials. We did not include bleeding-related mortality as a secondary outcome as most trials do not report this separately. Subgroup analyses were not undertaken because all of the included trials were at high risk of bias and the data required for the other analyses were not available or could not be extracted. We were able to undertake an analysis of the differential effects of banding and no treatment in participants with small or large oesophageal varices using data from one trial.